Title Page

Re-analyzed APOL1 kidney data support new ethics of 'race'

Authors:
Cyril O. Burke III[1*], Joshua Ray Tanzer[2], Leanne M. Burke[3]

[1] Department of Neurology, Brown University Health, Providence, Rhode Island, USA

[2] Biostatistics, Epidemiology, Research Design, and Informatics Core, Brown University Health, Providence, Rhode Island, USA

[3] Cardiovascular Institute, Brown University Health, Providence, Rhode Island, USA

[*] *corresponding author:*
E-mail: cyrilburke@alum.mit.edu (cob3)

ABSTRACT

OBJECTIVES

Persistent US 'racial' segregation racializes health, education, employment, and access. We hypothesized that selective recruitment into US military service, equal opportunity for military training and jobs, and earned access to Veterans Administration Healthcare could mitigate 'racial' differences created by racialized early-life deprivations and harms (i.e., social determinants of health). We examined veteran status and the starkest 'racial' disparity in healthcare—chronic kidney disease.

METHODS

First, we defined terms to ensure cross-cultural clarity by orienting international colleagues to the semantics of socially constructed 'race' (in Europe) and overt and subtle racialization of health (in the US). Second, we removed 'race correction' from estimated glomerular filtration rate and kidney failure under more equal conditions of US veterans. Third, we used data re-analysis and close examination of social cofactors to suggest alternative mechanisms for links between socially constructed 'race', apolipoprotein L1 gene variants, and racialized kidney disease.

RESULTS

There was no 'racial' disparity in kidney failure under more equal social conditions. Geographically localized "ancestry markers" may proxy for 'race'. 'Colorism' may be associated with apolipoprotein L1 variants linked to 'racial' (e.g., pigmentary) genes.

CONCLUSIONS

Under equal conditions, comparable outcomes should be the expected norm for all, regardless of socially constructed 'race', ethnicity, or nationality. Disparity between socially constructed categories implies disparate social conditions. International collaboration to discourage misuse of socially constructed 'race' in medical care and research is an actionable Population Health initiative with potentially high impact but low effort and cost.



STRENGTHS OF THIS STUDY

1. Reminds readers of cross-cultural conflicts in socially constructed 'race'.
2. Introduces international observers to racialization of health in the US.
3. Re-analyzes socially constructed 'race' under more equal conditions.
4. Applies new ethics, recommended by the National Academies of Sciences, Engineering, and Medicine, to older research on socially constructed 'race'.

1. INTRODUCTION

Note: Our manuscripts aim to provide a broad overview of an important problem. Exploring implications of complex social topics can exceed word, figure, and reference limits of modern medical publishing. A European reviewer wrote, "...nobody would read the current paper, even partially. Shorten, shorten, shorten please, and focus on the key message", insisting also that "The race part is irrelevant for the key point… and should be deleted in the opinion of this reviewer" (see comments to preCKD research [1]). **We explained that** 'race' is central to 'racial' disparities, and effects of genetic hypotheses on Population Health are small compared to harms stratified by socially constructed 'race'. **Eventually,** we relented. In segregating 'race', we extended our research by examining APOL1 under more equal conditions.

This "director's cut" has 9,700 words (shorter than a review article), not counting 3,300 words in block quotations or 2,300 words of supporting material (see Appendix). Reviewers and editors discouraged discussion of 'race' as commentary, offering the traditional approach to 'race' in medical publishing. **We explained that** 100 years of traditional scholarly articles failed to end misuse of 'race', but discussing ethical norms and hidden cofactors might inspire medical progress. **Eventually,** we found medRxiv.org. In Section 3.3.3, we discussed why some topics may need an alternative route to PubMed indexing.

US healthcare has a long history of basing reference norms on 'race'. Authors discussing the foundations in eugenics may have given the impression that bias in medicine is a historical artifact. Unchallenged for 'racial' inconsistency and selectively including or overlooking its influence, medical research can unwittingly promote 'racial' illusions that advance the myth of 'race' as biology. Hunt et al noted:

> …current health literature encourages clinicians to see their patients through a racial lens…. [T]he systematic inequalities that have been observed in the clinical care that racialized patients receive… likely reflect more than structural inequalities alone. They may also be attributable to this systematic authorization of race-based care. The arbitrary and contradictory ways the clinicians in this study understand and apply the concept of race raise concern that not only does using race to inform diagnostic and treatment choices lack scientific rigor, it may also put patients at risk of receiving nonstandard care [2].

The persistent use of socially constructed 'race' in US healthcare may seem unbelievable to decent, well-meaning international colleagues. That denial creates a stubborn obstacle to ending misuse of 'race'. In this paper, we will discuss the many ways 'race' is used in medicine, shaping daily practice in the US and internationally. First, this **Introduction** provides examples in Europe and the US to orient international readers to the illusions of socially constructed 'race' and 'ethnicity'. Next, we reanalyze published data to disentangle social factors, illuminating observed differences that inspire bad science (BS) in racialized countries. Finally, our deliberately comprehensive **Discussion** (with clarifying material in an **Appendix**) takes an approach not generally available through traditional medical publishing. After 100 years of failed efforts to eliminate misuse of 'race', the prospects for success may depend on a clear-eyed view of the ethics of 'race'. We therefore provide research and overview in a single article.

1.1 'Race' and ethnicity

"Race" and "ethnicity" are commonly used to describe population groups. Yet their socially constructed meaning has changed over time and between countries, and hidden assumptions may limit understanding by international colleagues.

In *The meaning of racial or ethnic origin in EU law*, the European Commission noted:

> In EU law, the Racial Equality Directive (RED) prohibits discrimination on the grounds of racial or ethnic origin without defining them…. In Europe, most groups targeted by racism categorically reject race as a label. Still, racialisation as 'a process that ascribes physical and cultural differences to individuals and groups' is thriving….
>
> Without real physical differences, people can be racialised on the basis of their perceived religiosity: the dress they wear or the way they cover their hair. Theories of Christianity's superiority over the Jewish and Muslim faiths can be traced back over centuries of European civilisation, and they laid the ground for anti-Semitism and Islamophobia. Poverty, too, can be portrayed as having its own culture, language and value system, thus poverty can also be racialised – particularly if a visible proportion of poor people belong to racial minorities….
>
> The traumatic experiences of the Holocaust and the urge to respond to apartheid provoked the scientification of race in legal terminology, which trapped racial in the confines of biological racism – the essence of the ideologies it originally set out to combat. Scientification disassociated racial from nation(al minority) and consequently severed cultural, religious and linguistic from it. Reducing the meaning of racial to 'biological' inevitably paved the way to essentialisation, while insulating it from the influence of social sciences….
>
> The invention of a supercategory with the intention of ensuring terminological unity and dispelling scientific misconceptions of race and racial origin at the international level had an unintended side effect in Europe. Here, the prism of nationalism resists the smooth transfer of terminological reform that followed WWII. While in **France**, ethnic origin is perceived as equivalent to race, in the **UK** it is separately defined in case law. In the rest of the EU, correlations between ethnic and racial occupy a central place in academic discussions and judicial interpretation [3].

Because everyone is confident in the local meaning of 'race', agreement on socially constructed 'race' between co-located subject and observer reflects 'shared illusion' rather than scientific "validity" [4,5,6,7,8,9]. And because conscious and unconscious

racist acts are perpetrated typically without prior inquiry, some ‘racial’ disparities may correlate better with ‘race’ perceived by others than with self-reported ‘race’ [10].

In 2022, Lu et al summarized contradictions and uncertainties in socially constructed ‘race’ and ethnicity [11]. They noted **(1)** lack of “consensus definition of race or ethnicity”, **(2)** inconsistency between subject and observer identification for other than Black or White ‘race’, and **(3)** “fluidity” of self-identification. Their aspirational recommendations called for “specific definitions” and “justification for collecting and analyzing” data on socially constructed ‘race’ in health research.

Subsequently, in a 2023 report on *Using Population Descriptors in Genetics and Genomics Research*, the National Academies of Sciences, Engineering, and Medicine (NASEM) stated:

> Race is neither useful nor scientifically valid as a measure of the structure of human genetic variation….
>
> Over the past several decades, a number of professional societies have developed statements or guidelines on race, ethnicity, human diversity, and multicultural practices…. In every case, the guidelines have been aspirational and intended to encourage their professional colleagues to become educated and informed….
>
> Despite the many recommendations, guidelines, and strategies… there has been relatively little change in how any entities within the genetics and genomics research ecosystem use these descriptors or require them to be used [12].

This is important because using ‘race’ in clinical decision making may overly reflect the cultural context and perspective of the healthcare provider, whether or not that is consistent with underlying biological processes.

1.2 Racialized US healthcare

Often providing ‘the best healthcare in the world’, US healthcare ranked last among high-income countries [13], and 48th of 50 for kidney-related mortality [14], **Fig 1**. Examining National Health and Nutrition Examination Survey (NHANES) data for CKD by ‘race’ and nativity, Ogungbe et al found that foreign-born non-Hispanic Black and White persons “…had a lower likelihood of CKD than those US-born”, and foreign-born Black adults had the lowest—51% lower than US Black adults [15].



Fig 1. Age-standardized kidney disease death rate per 100,000 in 50 selected countries (2017).

Fragmented US healthcare spends more per capita than any other nation [16]. In a decade, annual federal spending for chronic kidney disease (CKD) and kidney failure (KF) [17] almost doubled to $122 billion [18], or 1.8% of total federal spending, **Fig 2**.



Fig 2. Medicare spending on chronic kidney disease (CKD) and kidney failure (KF).

We focus on kidney disease as a major public health problem that also has significant differences between 'racialized' groups, in the US and worldwide.

1.2.1 'Racial' profiling, hypertension, kidney disease

Despite originating from various continents, studies under similar social conditions are relevant worldwide, regardless of the 'race' of the subjects (or lack of contrasting 'races'). Unless the underlying mechanisms of inequality are directly measured, recruiting 'racially diverse' subjects into medical research merely allows tracking of disparate treatment from lingering 'racial' segregation and structural racism [19,20].

In the US, CKD and KF represent the eighth leading cause of death, with lifetime risk varying by socially constructed 'race' [21,22], **Fig 3**, "one of the starkest examples of racial/ethnic disparities in health" [23]. Black people are 12% of the population but 35% of patients on dialysis. Ending 'racial' disparity in kidney disease for Black patients alone could redirect 20% of funds—$25 billion annually—from late-CKD to prevention [24]. Similarly excessive CKD affects Hispanic, Asian, and Native American people.



Fig 3. Lifetime risk of death in kidney failure (KF), with selected references. Solid and striped bars show KF death rates by US 'race' and ethnicity. Clear bars show death rates for other causes (combined sexes).

US kidney disease mortality rates (per 100,000 per year) vary by city (White patients from 2.0 in San Diego to 18 in Indianapolis, Black patients from 7.9 in New York to 45 in Charlotte) [25], suggesting environmental cofactors. A different geographic pattern in

the ratio of Black-to-White kidney mortality, **Fig 4**, suggests racialized cofactors may contribute to "…a 13-year difference… between Black and White life expectancies in Washington, DC" [26], and in Boston, "Black males lived an average of 71.8 years, about 9.3 fewer years than other males in Boston, who lived 81.1 years" [27,28]. For dialysis care, Ashkar et al showed:

> …poorer outcomes (higher mortality, hospitalization, readmission, anemia, catheter use, and hyperphosphatemia); lower rates of fistula use; and lower dialysis adequacy… were more prevalent in regions with lower income, higher unemployment, and lower college education, and they served populations with greater proportions of Black and Hispanic residents…. concentrated in the southern and western United States [29].



Fig 4. Ratio of Black to White mortality from kidney disease in largest US cities (2014-2018).

There are numerous "racially segregated US hospital markets" [30]. "Low-income minorities with bad health had 68% less odds of being insured than high-income Whites with good health" [31]. At some academic centers, Black patients were more likely to be deemed "teaching cases" for training the medical students, residents, and fellows. In 2003, the National Academy of Medicine reported on "Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care" [32], but 20 years later, "There hasn't been a lot of progress…. We are still largely seeing what some would call medical apartheid" [33].

Coincidentally, data collected to monitor and remedy 'racial' disparities can worsen them, for example, by misuse in clinical algorithms [34] and popular point-of-care clinical decision-making tools [35,36]. Hunt and Kreiner noted the consequences for primary care:

> …that racial/ethnic group differences are so readily equated with presumed genetic differences, and that the idea of "Personalized Medicine" can so ironically be converted into carte blanche for practicing racialized medicine [37].

Limitations in the medical literature further engrain this problem, with studies often leaving out key information that could be relevant to 'racial' disparities. For example, dehydration is prevalent among Black people [38], causes more acute kidney injury (AKI) in low-income areas [39], and increases CKD risk [40,41]. US treatment guidelines for hypertension in Black patients favor thiazide diuretics [42,43] that can worsen dehydration. A study recommending against diagnosing KF while on thiazides noted thiazide-to-loop-diuretic usage ratios of 1.06 for White and 1.66 for Black subjects but omitted KF by 'race' [44]. A study recommending systolic blood pressure control to less than 120 mm Hg (to reduce cardiovascular mortality) reported no benefit in Black subjects [45] but omitted their 100% increase in AKI (until years later [46]). A study recommending a thiazide for poorly controlled hypertension in advanced CKD reported chlorthalidone tripled the number of subjects with AKI, and increased AKI episodes per subject by 50%, but omitted AKI by 'race' and reliance on a 'race-corrected' eGFR that underestimates CKD and its severity in Black people [47]. Whether due to a peer review process insensitive to the nuanced, socially underpinned ways 'race' could result in observed differences, or due to authors choosing to omit this information to avoid complex topics, the result of this publication bias is the same: an oversimplification that subtly engrains stereotyped healthcare.

1.2.2 'Race correction'

One of the most common ways that 'race' is codified in medical practice is the use of a 'race correction'. The first 'race correction' for estimating glomerular filtration rate (GFR), in 1999, led to more estimated GFR (eGFR) 'corrections'—for ethnicity in the US [48] and nationalities in Asia [49,50,51,52]. Laboratory reporting of 'race corrected' eGFR results led to questioning [53,54], and the "…majority of studies found that removal of race adjustment improved bias, accuracy, and precision of eGFR equations for Black adults" [55]. Those condemning the "…inappropriate use of race in nephrology" distinguished mistreating individuals from monitoring the effects of racism on a population [56]. However, others hailed "race-free" equations as a "successful compromise" that removed 'race' only from the equations [57]. Reports that "race-free" eGFR equations "underestimated measured GFR in Black participants… and overestimated measured GFR in non-Black participants" [58] merely shifted misuse of 'race' to pre-test "population weighting" [59,60], potentially delaying care for Black patients [61] in a way much harder to detect and stop.

After modifications for Black candidates who were disadvantaged by the 'race-based' equations, monitoring kidney transplantation by 'race' showed improved access for Black candidates "…with no significant change in overall transplant" for others, which should encourage "…efforts by health systems, medical societies, and policymakers to actively redress harms, rather than limiting interventions to the replacement of race-based algorithms" [62].

1.2.3 Motivation and outcomes

The problem with 'race' in medical research relates largely to methodology. Research is limited by the relevance of the research question and operationalizations of traits compared, connecting theoretical constructs and empirical data through research procedures or indicators. The old adage, "garbage in, garbage out", is the fundamental problem with BS (bad science). Many consumers of scientific research view the process as objective, providing factual answers to questions posed. Indeed, a well designed and implemented study may provide clear evidence for or against a hypothesis. However,

the relevance and rigor in testing that hypothesis always have limitations, especially for something nuanced like 'race'.

Counter to the narrative of objective research, a preeminent scholar on the philosophy of science, Thomas Kuhn, presented 'science' as inherently social [63]. Articles discussing socially constructed 'race' as a proxy for social determinants of health (SDOH) are often labeled social 'Commentary' [64]. Articles proclaiming the objectivity of quantitative analysis [65], and that "…a race stratified eGFRcr (i.e., separate equations for Blacks and non-Blacks) would provide… the best medical treatment for all patients" [66], miss how confirmation bias influences what numbers we collect, how we understand that data, our confidence in what we are doing now, and which articles get published.

Ultimately, that is the challenge. Data tell us what happened, not why. Focusing on predictive risk factors to surpass the limitations of causal inference allows misattributions of the underlying mechanisms of difference. More than an abstraction, this methodological concern has practical implications for how we help patients, and how we fail them. Invoking 'race', a non-modifiable risk factor, gives the impression that nothing can be done to help. That said, the social conditions in which we live that give rise to differences based on racialized groups are modifiable. To neglect this would change the ways we understand what can be done to improve as healthcare providers.

Racialized practices—ongoing despite 100 years of academic articles in Anthropology that 'race' is a myth—inspired our data re-analysis (see **Results**) and examination of socially constructed 'race' as a proxy for implied social cofactors (see **Discussion**). To end misuse of 'race' is an overdue Kuhnian paradigm shift [63,67,68].

"With malice toward none, with charity for all" [69], we re-examined 'race' in kidney disease. Removing 'race correction' from GFR estimates of Black and White veterans showed comparable results. Re-analyzing two studies in Black veterans of gene variants associated with kidney risk—both published before NASEM guidance [12]—gave insights into the influence of socially constructed 'race'.

2. RESULTS

2.1 Removing 'race correction'

To demonstrate the practical implications of the 'race correction', first we reanalyzed data to remove 'race correction' from GFR estimates. We considered an impressive study of KF versus eGFR in 1.70 million White veterans (4% female) and 311,000 Black veterans (6.1% female) [70] to investigate the public health implications and test the hypothesis that differences between arbitrary groups would be less after comparable conditions of selection and opportunity.

2.1.1 Equal outcomes despite 'race'

Fig 5 shows baseline veteran characteristics and renal comorbidities (all significant to $p<0.001$), with Black veterans more likely to be younger, female, hypertensive, diabetic, in the highest and lowest eGFR ranges, and living in lower-socioeconomic-status zip codes **(left)**, the latter also shown graphically **(right)**.

Baseline Characteristics of Outpatient Veterans by 'Race'		
Characteristic	Black	White
Total (%)	311,790 (15.5)	1,704,101 (84.5)
Age, mean ± standard deviation (years)	59.1 ± 13.8	**66.0 ± 12.4**
Female Sex (%)	**6.1**	4.0
Estimated glomerular filtration rate, mL/min/1.73m2 (%)		
≥90	**44.2**	21.5
60-89	42.5	**56.3**
45-59	8.2	**15.2**
30-44	3.3	**5.5**
15-29	1.4	1.4
<15	**0.4**	0.2
Comorbidities (%)		
Hypertension	**70.5**	67.7
Diabetes mellitus	**31.5**	29.1
Coronary heart disease	25.7	**39.4**
Chronic obstructive lung disease	23.3	**30.0**
Stroke or transient ischemic attack	12.3	**15.6**
Heart failure	12.0	**15.8**
Peripheral arterial disease	10.7	**15.4**
Dementia	**5.6**	5.5
Hepatitis C virus infection	**5.3**	2.1
Atrial fibrillation	4.8	**10.6**
Human immunodeficiency virus infection	**2.6**	0.4
Socioeconomic status (SES), tertile (%)		
Low	**55.6**	29.9
Middle	24.6	**35.0**
High	19.8	**35.2**

Comorbidities ranked by frequency in Black veterans. Bold type marks higher prevalence of each comorbidity in Black or White veterans (p<0.001 for all) and diabetes mellitus and hypertension as the major risk factors for chronic kidney disease. Residential zip code allowed crude estimatation of each subject's SES.



Fig 5 (left): characteristics of veterans in the primary source by 'race', all cofactors with p<0.001, **(right):** veteran socioeconomic status, approximated (in the primary source) by zip code.

The Modification of Diet in Renal Disease (MDRD) eGFR 'race correction' for Black veterans can be removed by simply dividing by 1.21. Making this adjustment shifted rates for KF risk and eGFR prevalence to lower GFRs, **Fig 6**, also shown graphically in **Fig 7**. The X-axis 'race corrections' (horizontal arrows) sometimes had significant Y-axis effects (vertical arrows). The revised KF outcome curves (increasing to the left) overlapped for Black and White veterans (inset). The revised eGFR-prevalence curves (increasing to the right) showed higher prevalence of lower eGFRs in Black veterans. This demonstrates how, under similar conditions, the paradox of low prevalence of early CKD yet faster progression at late stages appeared to be a mathematical artifact of 'race correction'.

Removing 'race' from primary data, 1st and 2nd tables

4-variable MDRD estimated glomerular filtration rate, mL/min/1.73m^2 (%)

Range of eGFRs	Upper limit of eGFR	White		Black		
		Percentage	Cumulated %	Limit / 1.21	Percentage	Cumulated %
≥90	undefined	21.5	100	undefined	44.2	100
60-89	**90**	56.3	**78.6**	**74.4**	42.5	**55.8**
45-59	**60**	15.2	**22.3**	**49.6**	8.2	**13.3**
30-44	**45**	5.5	**7.1**	**37.2**	3.3	**5.1**
15-29	**30**	1.4	**1.6**	**24.8**	1.4	**1.8**
<15	**15**	0.2	**0.2**	**12.4**	0.4	**0.4**

Age-standardized rates of kidney failure (per 1,000 person-years)

Range of eGFRs	Upper limit of eGFR	White	Black	
		KF rate (95% CI)	Limit / 1.21	KF rate (95% CI)
≥90	undefined	0.2 (0.1, 0.3)	undefined	0.4 (0.2, 0.6)
60-89	**90**	**0.1 (0.1, 0.2)**	**74.4**	**0.4 (0.3, 0.4)**
45-59	**60**	**1.7 (1.5, 1.8)**	**49.6**	**6.3 (5.7, 7.0)**
30-44	**45**	**12.5 (11.8, 13.1)**	**37.2**	**32.8 (30.4, 35.2)**
15-29	**30**	**94.3 (90.7, 97.9)**	**24.8**	**179.5 (169.8, 189.3)**
<15	**15**	**472.3 (448.3, 496.4)**	**12.4**	**615.6 (571.0, 660.3)**

Note: Numbers in parentheses are limits of the 95% confidence interval. **ABBREVIATIONS: CI = confidence interval, cumulated % = sum of percentages of eGFRs (y-axis) below the upper limit (x-axis), eGFR = estimated glomerular filtration rate, KF = kidney failure, MDRD = Modification of Diet in Renal Disease, mL/min = milliliters per minute.**

Fig 6. Removing 'race correction'. Dividing the upper limit of eGFR range for Black patients by the 1.21 'race correction' numerically removed 'race correction', shifting their results to lower numbers on the X-axis.



* = **Age-standardized events per 1,000 person-years,** ** = Sum of percentages in lower eGFR ranges.

Fig 7. Removing 'race correction'. Dividing by 1.21 shifted X-axis values to the left (blue curves). Horizontal and vertical arrows show X- and Y-axis shifts from 'race correction'. **Curves increasing to the left:** kidney failure (KF) curves for Black and White veterans overlap within their 95% confidence intervals (inset). **Curves increasing to the right:** 'race correction' falsely lowered cumulated Y-axis eGFR percentages of Black veterans.

To further investigate, we also employed a more precise regression modeling approach. When estimating the magnitude of associations between inverse eGFR and KF rates with and without 'race correction', the ratio was exactly 1.21, as expected ('race corrected': beta = 11700.74; correction removed, beta = 9670.03; ratio = 1.21). However, as hypothesized, when removing the 'race correction', White and Black patients had more similar associations between serum creatinine and GFR (t (10) = 0.91, p = 0.3860) than when 'race correction' was maintained (t (10) = 2.36, p = 0.0402). This supports that the 'race correction' is mathematically inducing differences that would not be identified if no 'race correction' were employed.

There are some limitations that should be noted. We are suggesting the null hypothesis of no difference between White and Black veterans is true, even though this is hard to conclusively demonstrate. Additionally, the sample size was small—only 15 data points. This is because the continuous reported data we could reanalyze were segmented into five ranges, meaning five estimated averages available for reanalysis as data points for each of White veterans and of Black veterans with and without 'race correction'. Because of this, the precision of this exact result may not hold up with replication. Yet despite these limitations, the results are still consistent with the concerns raised about an artifact of arithmetic driving differences in kidney disease diagnosis. It contradicts notions that Black Americans have less early CKD and need less early care. Instead, if Black Americans had the same GFR estimates as White Americans, we have no evidence to suggest their treatment prognosis would be any different.

2.2 APOL1, AKI, and COVID

Another concern we have is for the presumed genetic basis of 'race' in KF. Hung et al studied the effects of apolipoprotein L1 (APOL1) risk variant (RV) alleles among 990

participants in the Department of Veterans Affairs Million Veteran Program with “African ancestry” and hospitalized with coronavirus disease 2019 (COVID-19) [71]. It is suggested that a variant of the APOL1 gene that is more common in Sub-Saharan West Africa, because it is protective against sleeping sickness in that area, also confers a risk for KF. While we do not contest the prevalence of this variant in the African diaspora, it is less clear whether this genetic variant is or is not the mechanism by which there are differences in KF rates between racialized groups.

Fig 8 shows AKI rates with and without various cofactors, ordered by odds ratios (ORs). They found the relative risk (RR) of AKI was 1.35 times higher for *APOL1* “high-risk” (HR) genotype (*APOL1* HR = 2 RV copies) than “low-risk” (LR) genotype (*APOL1* LR = 0 or 1 RV copy). However, RR of AKI was 2.4 for mechanical ventilation and 2.63 for vasopressor use, both more common in the *APOL1* HR group.



Fig 8. Acute kidney injury rates for various cofactors in veterans hospitalized with COVID-19. Possible direct or indirect AKI cofactors ordered by odds ratios (ORs), the greatest risk correlating with indicators of poor health.

Mechanical ventilation and vasopressors showed the largest RRs, consistent with findings that AKI in veterans with COVID-19 varied with severity of illness [72]. Verbeek et al recommended correcting bias in observed RR using the “reference confounder” with the largest effect [73]. Unconfounding the *APOL1* RR of AKI with vasopressors alone reduced the RR to 1.09, **Fig 9**.

Bias correction for reference confounders

Relative risk (RR) of AKI in high-risk vs low-risk APOL1 in veterans hospitalized with COVID-19

	No.	AKI (outcome)		Mechanical ventilation		Vasopressors	
APOL1 risk variant group (exposure)							
High-risk (2 RVs alleles)	125	64	51.2%	22	17.6%	17	13.6%
Low-risk (1 or 0 RV alleles)	865	328	37.9%	119	13.8%	81	9.4%
RR, high-risk to low-risk APOL1			**1.35**		**1.28**		**1.45**
Mechanical ventilation							
With	141	112	79.4%				
Without	849	280	33.0%				
RR, with to without mechanical ventilation			**2.41**				
Vasopressors							
With	98	88	89.8%				
Without	892	304	34.1%				
RR, with to without vasopressors			**2.63**				

"Sensitivity to unmeasured residual plausible confounding"		
RRobs	**1.35**	
E-value	2.04	
Reference confounder		
	Mechanical ventilation	**Vasopressors**
RRco	**2.41**	**2.63**
RRce	**1.28**	**1.45**
Bias Factor (BF)	1.15	1.24
Unconfounded APOL1 relative risk of AKI		
RRobs / BF	**1.18**	**1.09**
See Verbeek et al doi: 10.1016/j.envint.2021.106868		

ABBREVIATIONS: AKI = acute kidney injury, APOL1 = apolipoprotein L1, BF = bias factor, E-value = "how large the effect of a confounder would have to be to reduce an observed RR to the null value" (see Verbeek et al), No. = number, RR = relative risk, RRce = RR of confounder exposure association, RRco = RR of confounder outcome association, RRobs = observed RR, RRobs / BF = unconfounded RR, RV = risk variant.

Fig 9. Bias correction for reference confounders. Correcting effects of vasopressors and mechanical ventilation on AKI outcomes reveals unconfounded relative risk (RR) of *APOL1* high-risk versus low-risk genotypes. Correlation between mechanical ventilation and vasopressors was not 100 percent, so unconfounded AKI risk would be even closer to unity on adjusting for both.

2.2.1 COVID-19 in US vs Brazil

To ensure that these findings are not exclusive to the US, we compared available findings between the US and Brazil, results presented in **Fig 10**. This includes data from a similar study of COVID-19 and AKI in the Brazilian general population [74]. Although confidence intervals are much wider for the Brazilian sample due to a smaller sample size, the ORs between Brazil and the US are close for many cofactors.



Fig 10. Acute kidney injury (AKI) odds ratios (ORs) for cofactors during hospitalization with COVID-19. Forest plot of AKI ORs (with 95% confidence intervals) suggests similarity of cofactors between US veterans and Brazilian general population despite differences in genetic origins and socially constructed 'race'.

Many covariates showed statistically "small" effects (ORs below 1.68), some small enough to suggest random chance. Signs of critical illness showed "large" effects (ORs above 6.71). Urine characteristics had ORs primarily toward the upper range, highlighting their importance. The low OR for "dipstick hematuria, year prior" [rows 49 and 61] might reflect two sub-populations: women (some menstruating) and men (hematuria always abnormal). This demonstrates how, in the greater context of patient acuity, the RV allele of the *APOL1* gene does not characterize very large differences between racialized patient groups.

2.3 APOL1 and N264K

A second important study by Hung et al of 121,000 from the Million Veteran Program with "African ancestry" (13.8% female) compared CKD in patients with *APOL1* HR versus LR and with and without N264K (a second-site *APOL1* variant) and noted, "presence of a single copy of the *APOL1* p.N264K mutation mitigated the increased risk conferred by two *APOL1* HR variants" [75]. About 20% of their data came from smaller studies in the general population, but our re-analysis used only 80% of their data, from veterans.

Fig 11 shows the percentage of subjects by kidney outcomes for four combinations of *APOL1* HR or LR and N264K alleles present (**+**) or absent (**-**) [75]. Black bars, representing *APOL1* high-risk genotype without N264K (*APOL1* HR, N264K**-**), show the highest rate for every kidney outcome. Blue bars represent the largest group, *APOL1* low-risk genotype without N264K (*APOL1* LR, N264K**-**). Note that presence of the N264K allele (N264K**+**) in just 3.8% of *APOL1* LR and 0.5% of *APOL1* HR patients means orange and green bars combined represent less than 5% of subjects, with small absolute numbers (population times rate) in their CKD and outcome groups.



	No. (% of total)	CKD after enrollment	Proteinuria ≥ 1+	CKD prior to enrollment	KF after enrollment	Nephrotic Syndrome	KF prior to enrollment	FSGS
APOL1 LR, N264K-	101,216 (83.3%)	6.21%	12.59%	13.06%	1.51%	0.68%	1.43%	0.08%
APOL1 HR, N264K-	15,022 (12.4%)	6.44%	15.84%	17.82%	2.49%	1.27%	4.53%	0.35%
APOL1 LR, N264K+	4,672 (3.8%)	5.63%	12.61%	13.31%	1.63%	0.75%	1.28%	0.06%
APOL1 HR, N264K+	582 (0.5%)	6.36%	14.60%	10.82%	0.69%	0.69%	1.72%	0.17%

NOTE: Million Veteran Program "enrollment" includes approximately annual research newsletters and updates with contact information to maintain "engagement". **ABBREVIATIONS:** APOL1 = apolipoprotein L1, CKD = chronic kidney disease, FS = focal segmental, HR = high-risk, KF = kidney failure, LR = low risk, OR = Odds Ratio (APOL1 HR, N264K- vs APOL1 LR, N264K-).

Fig 11. CKD and kidney outcomes in veterans by *APOL1* and N264K status. Ordered by odds ratio (OR) of kidney outcome between *APOL1* low-risk versus high-risk without N264K allele (N264K-)—less than 5% of subjects were positive for N264K (N264K+). Note the improvement in outcomes after study "enrollment".

The chart is ordered by OR between the two largest groups without N264K (N264K**-**), representing 95% of Black veteran subjects and differing only by *APOL1* HR vs LR. Note for *APOL1* HR N264K**-** the association of lower rates of KF and CKD after than before Million Veteran Program "enrollment" [76] and that, after enrollment, rates of CKD were the same for all four groups. This is important because attributing KF and CKD to an inherent genetic problem can give the impression that there is limited ability to intervene. The similarity of CKD rates after enrollment suggests that all patients could benefit from treatment, even if there are differing acuity levels at baseline.

3. DISCUSSION

The goal of this paper has been to elucidate the contextual circumstances that could explain observed differences in kidney function between racialized groups. While Black patients may be more likely to experience problems with kidney function, appropriate identification of the mechanism by which this occurs is essential to improving health outcomes. Attributing differences to a biological difference with a genetic basis is methodologically dubious and can disincentivize efforts to improve the public health conditions that are more relevant to population well-being.

Bioethical oversight of ‘race’ falls under a principle defined after decades of misuse of ‘race’ by the US Public Health Service [77,78], **Fig 12**. Yet, misuse of ‘race’ as a conscious or unconscious input for clinical care persists, even among those aware of its scientific invalidity [79], and the Food and Drug Administration’s (FDA’s) approval of race-specific medicines “…has not been challenged as a Fourteenth Amendment violation” [80,81,37]. Voluntary corrective guidelines “…have had little effect on how these concepts are deployed” [82]. Even the comprehensive, scholarly NASEM recommendations are voluntary [12].

Institutional review of bioethical principles in US medical research			
Concern	**Human subjects**	**Health information**	**Misuse of 'race'**
Bioethical principle	**Autonomy**	**Privacy**	**Justice**
Date of original legislation	US National Research Act **1974**	US Health Insurance Portability and Accountability Act **1996**	US Constitution Fourteenth Amendment **1868**
IRB oversight	**Strict**	**Strict**	
Federal budget	National Institutes of Health **$52 billion 2022**	Nominal	Medicare expenses for CKD + KF **$123 billion 2020**
'Racial' disparity	**Poorer outcomes by 'race'** Systemic misuse of 'race'	**No physical threat**	**Tripled kidney failure risk** for US Black patients
Health literacy	**Significant health illiteracy** regardless of 'race'	Indirect	**Doubled reading failure** in US hypersegregated schools
Population at risk	"…children, prisoners, impaired decision-making, **economically or educationally disadvantaged"**	**No physical threat**	**Economic, educational, and healthcare deprivation** of uniquely hypersegregated US Black neighborhoods
ABBREVIATIONS: CKD = chronic kidney disease, IRB = institutional review board, KF = kidney failure, Medicare exp. CKD + KF = total Medicare expenses for CKD plus KF, 'race' = United States social taxonomy of 'race'.			

Fig 12. Bioethics: Autonomy, privacy, and justice in United States (US) healthcare. ‘Race’ collected to monitor progress in ‘racial’ disparities can be misused in clinical care. The principal of Justice could inspire oversight.

‘Racialized’ data can wrongly suggest biology in different outcomes by socially constructed ‘race’. However, ‘race’ is a myth. Despite centuries of claims of biological difference, ‘race’ was absent under the high standards of the Cochrane Reviews. A study of 1,000 randomly selected Cochrane Reviews, published between 2000 and 2018, showed that only 14 (1.4%) had planned to include subgroup analysis by ‘race’ [83], and in those 14, there was only a single ‘racial’ finding of statistical significance.

From any continent, studies under equal conditions (e.g., even so-called “single race” studies) should be equally informative. The lowest KF mortality rate (i.e, of the most privileged group in the ideal environment) should be the goal for all. Different outcomes reflect social inequality.

To avoid perpetuating false notions of biological ‘race’ [84,85,86], we often label it “socially constructed” and always put ‘race’ or ‘racial’ in quotation marks [87,88].

3.1 Removing ‘race correction’

Our re-analysis found Black and White veterans share the same curve for KF, suggesting cofactors of veteran status minimized ‘racial’ disparities, **Fig 7**. In this section, we consider alternative explanations that could explain observed differences between racialized groups.

3.1.1 Comparable conditions

(a) Screened volunteers

Implied (but typically unstated) in studies of US veterans are the educational and physical selection standards of the US Armed Services [89]. Long before veterans enrolled in research, servicemembers met written requirements that screen out most of the widespread US functional illiteracy [90], **Fig 13**, and physical requirements (including urine tests) that precede comparable access to military training, jobs, and healthcare. With rare exceptions, servicemembers earned access to Veterans Administration (VA) Healthcare by completing basic training, entering active duty, and serving honorably. Basic training (e.g., to avoid dehydration) may promote relevant habits in veterans.



Fig 13. Late illiteracy: percentage of Black and White 4th grade students reading below basic level.

(b) Segregation

The European Commission noted that racial or ethnic discrimination "…can lead to a cycle of disadvantage which is frequently passed from one generation to the next" [3]. However, US military communities are integrated, and Black service members fared better than Black civilians on numerous metrics [91]. Black and White veterans had similar employment rates [92] and more similar socioeconomic status, **Fig 5**, in contrast to what Peterson and Krivo showed as the relative advantage/disadvantage of US Black and White neighborhoods [93], **Fig 14**. The actual economics of Black and White veterans might be closer because socially constructed 'race' influences residency options and choices. For example, Sampson and Bean noted, "…implicit bias in perceptions of crime and disorder may be one of the underappreciated causes of continued racial segregation" [94].



Fig 14. Distribution of advantages and disadvantages of US White and Black neighborhoods.

(c) 'Racialized' healthcare

Healthcare access is increased by higher income, having insurance, and higher education. In the general population, Takkavatakarn et al found higher income associated with lower CKD risk overall but unexpectedly associated with higher CKD risk in *APOL1* HR individuals [95]. Similarly, on stratifying the general population by self-identified 'race', Grobman et al found:

> …higher income, having insurance, and higher education were associated with a lower prevalence of CKD among White adults but not among Black adults…. [96].

In the general population, it is intriguing that something associated with exposure to healthcare might, paradoxically, increase CKD risk in higher-income individuals with *APOL1* HR genotype and in Black adults with higher income, having insurance, and higher education. Thiazide diuretics worsen dehydration, so perhaps *all* hypertensive patients should start renoprotective ace inhibitors, even those with *APOL1* HR genotype [97,98].

(d) Stereotyping

Black patients survive longer on dialysis. A study of dialysis survival after hospitalization for major medical illnesses blamed stereotyped personality traits, suggesting that White patients give up on dialysis sooner than Black patients, who (supposedly) have a greater sense of hope for the future after enduring hardships [99,100]. However, alternative explanations might include 'racial' differences in stroke mechanisms [101], dementia [102], and other processes that 'racialize' health [103]. The thiazide diuretics recommended for Black patients increase dehydration, serum creatinine, and AKI [44,45,46], possibly contributing to too early diagnosis of kidney failure and too early initiation of dialysis.

Stereotyping (e.g., lacking trust in healthcare [104], lacking advance care planning [105], etc, [106]) is another example of victim blaming [107,108] that, whether negative or positive, distracts from seeking root causes. There is irony when the kettle pot of Blackness labels Black Americans as "lazy" [109]. Green noted, "…encouraging people to recognize information that is consistent with stereotypes may be helpful in dispelling damaging stereotypes within society" [110].

(e) Simpson's Paradox

Until confounding factors are characterized and controlled for, analyzing veterans separately from the general population may avoid Simpson's Paradox, whereby results imply opposite findings based on whether or not estimates are stratified by key subgroups [111]. Peterson et al showed higher baseline comorbidities and illness severity yet equal or lower mortality among Black veterans in VA healthcare in all but six diseases [112] (or five, after our re-analysis). Despite a higher COVID-19 infection rate among minority women veterans, Tsai et al found equal complications of mortality, cardiovascular events, or onset of heart disease regardless of 'race' [113].

3.2 'Race' and genetics

3.2.1 Inconsistency of 'race'

'Race', 'mixed race', 'biracial', 'multiracial': these terms are all scientifically invalid inputs for healthcare [12]. The mechanism of action of socially constructed 'race' and *APOL1* genotypes in CKD must account for inconsistencies in folk taxonomies of 'race' [114,115,116,117]. For example:

South Africa:

> Evidence for race was found most familiarly in skin colour. But this was not necessarily the overriding or conclusive factor…. where they were born… had gone to school… where and with whom their children played… type and place of work… religious affiliation…. For example, a magistrate pronounced as Coloured a fair-skinned woman who was widely accepted as white…. prompted, it seems, by the fact that this woman had recently converted to Islam [118],

Nigeria:

> When I came to the United States, I hadn't stayed very long, but I already knew that to be "black" was not a good thing in America, and so I didn't want to be "black."... It took about a year of reading, learning, watching, for me to really come around and realize that there's a context. [109],

Brazil:

> …there appears to be no racial descent rule operational in Brazil and it is possible for two siblings differing in Color to belong to completely diverse racial categories…. asked about their origins (the question admitted multiple responses) <10% of Brazilian black individuals gave Africa as one of their answers [119,120].

'Racial' classification in the US dates to a 1662 statute [121] reflected in this segregation-era US Census instruction:

> "A person of mixed white and Negro blood should be returned as a Negro, no matter how small the percentage of Negro blood" [122,123].

In summary, the invention and tailoring of 'race' for local populations has a direct impact on the literature. As noted above, authors and subjects in different countries absorb conflicting local myths for coding 'race' (see **Appendix: 5.5 Black is White**). Electronic health records are often unclear who chose the label (i.e., actual patient self-report of personal identity versus healthcare provider assessment of skin color versus billing clerk [124]) and are unreliable [125]. The conflicting taxonomies cannot be collapsed into a single validated determination of 'race'. Changing 'racial' definitions and coding in large databases used for public health research thus produce unreliable findings that vary based on when, where, and by whom data was collected and articles written.

3.2.2 Colorism and APOL1

India:

> Early attempts to classify race in India… relied on anthropometric measurements and often reinforced colonial biases…. categorized the Indian population into seven "physical types. …Colorism, with its preference for lighter skin tones, remains a pervasive issue, reflecting the enduring legacy of colonial influences and cultural norms [126].

"Colorism" varied the abuse of racism to stratify and stabilize 'racial' hierarchies, correlating increasing pigment with worse deprivation:

> …the most effective way to segregate black people was to "use the dark skin slaves vs. the light skin slaves and the light skin slaves vs. the dark skin slaves.".… Subsequently, colorism became an effective strategy in colonizing and dividing people [127].

The odds of inheriting two, one, or zero copies of *APOL1* RV alleles vary, for example, with the number of great-grandparents of West African origin. With eight high-risk West African great-grandparents, all with *APOL1* HR genotype (i.e., two RV alleles), a subject will inherit two RV alleles. A subject with seven White great-grandparents and only one West African high-risk great-grandparent is considered Black in the US, "usually looks white or almost so" [128], and the odds of inheriting RV alleles are 75% for zero copies, 25% for one, and zero for two copies.

In contrast, N264K**+** is more common in Europeans, found in less than 5% of Black patients, and "…mutually exclusive with the *APOL1* G1 allele…. the presence of a single copy of the *APOL1* N264K mutation mitigated the increased risk conferred by HR *APOL1* genotypes" [129].

With *APOL1* RVs more common in West Africa and N264K**+** more common in Europe, people with one or the other regional distribution marker likely have different physical appearance and lived experiences. Thus, geographically localized "ancestry markers" can be proxies for 'race', and colorism can be a mechanism stratifying subjects even in ostensibly 'single-race' studies.

3.2.3 Confusing 'race', ethnicity, ancestry, and geography

Commonly used terms for socially constructed population groups are ethnicity in Europe and 'race' in the US. 'Race', ethnicity, and ancestry are different (albeit similar and overlapping) concepts and all are subject to misuse.

NASEM recommended against conflating 'race' with ancestry:

> Conclusion 4-2. Using socially constructed groupings indiscriminately in human genetics research can be harmful. Their use reinforces the misconception that differences in social inequities or other factors are caused by innate biological differences and diverts attention from addressing the root causes of those social differences, which compromises the rigor and potential positive effect of the research. **Recommendation 1. Researchers should not use race as a proxy for human genetic variation. In particular, researchers should not assign genetic ancestry group labels to individuals or sets of individuals based on their race, whether self-identified or not** [12].

Hung et al were not clear on what they meant by 'race' but expressed confidence in 'race' in their analytic approach to substantiate apparent relationships between 'race' and personal ancestry [71,75]. They described selecting a subset from the Million Veteran Program databank "…with genetic information available, of African ancestry" and used the method of "genetically inferred ancestry" described by Fang et al, in 2019 [130]. Their approach used principle components analysis to identify people with similar genetic profiles, which also tended to show overlap with racialized groups.

The problem with conflating 'race' with genetic history is more than a math problem to optimize for greatest predictive accuracy. People who look similar truly are more likely to have a shared ancestral background, and by extension some genetic overlap. What is missing from the discussion is all the other social context that comes with ancestral history and appearance. Because of the long history of colonialism, slavery, and global migration, genetics cannot be separated from this confound. In many cases, 'race' will predict differences in many outcomes. But it would be difficult to distinguish a molecular genetic cause from everything else implied by shared ancestral background. People with the same ancestral background may look similar, but that also will impact the way they are treated in daily life. Additionally, that same ancestral background may shape generational wealth due to the history of slavery and colonialism. To presume the mechanism of difference is genetic overlooks all the other reasons for difference, especially when it is difficult to separate 'race', ethnicity, genetics, and ancestral history.

NASEM subsequently noted:

> There is a pervasive misconception and belief that humans can be grouped into discrete innate categories…. The illusion of discontinuity between racialized groups has supported a history of typological and hierarchical thinking…. These modes of thinking often spill over to other descent-associated population descriptors such as ethnicity and ancestry (Byeon et al., 2021; Fang et al., 2019). The structure of human genetic variation, though, is the result of human population movement and mixing and so is more related to geography than to any racial or ethnic classification [12].

3.2.4 'Race' in research design

NASEM noted:

> Conclusion 4-8. In the absence of measured environmental factors, researchers often wrongly attribute unexplained phenotypic variance between populations to unmeasured genetic differences. **Recommendation 4. Researchers conducting human genetics studies should directly evaluate the environmental factors or exposures that are of potential relevance to their studies, rather than rely on population descriptors as proxies** [12].

The data from Hung et al are valuable but needed to be explored [71,75]. The 'single-race' study design presupposed an association between genetic biology and 'race', made analytic assumptions which overlook more direct causes of AKI that may exist, whether or not captured in data. This results in the appearance of *APOL1* genotypes justifying the myth of 'race' as biology.

The directed acyclic graph (DAG) [131] in **Fig 15** is a causal framework the study might have imagined, in modeling their choices, but with our modifications to show potential "back door paths" that could explain the outcomes better than a direct effect of APOL1. The grey oval represents their focus on biology with no attempt to consider possible differential effects of racism between *APOL1* HR and LR genotypes. Their meta-analysis models included some demographic variables, but none related to education, employment, colorism, socioeconomic status, or any other SDOH, ignoring all the context our re-analysis of veterans suggests is important. Nor did they justify choosing <u>any</u> variables for the analysis, which is important because adding more to a model can introduce selection bias by way of Simpson's paradox.



Fig 15. Causal directed acyclic graph (DAG) that the study might have imagined (with our modifications). One back door path from *APOL1* to kidney disease is via West African ancestry (i.e., West African ancestry increases odds a person has *APOL1* high-risk copies but also alters physical appearance, and physical appearance feeds discrimination). The study assumed the 10 ancestry principal components (plus other variables in other models) analytically controlled for this to justify focusing on relationships in the shaded area. First, we disagree that ancestry principal components controlled for the back door path via skin tone. Second, even if principal components addressed the confound of skin tone, that does not account for the history of discrimination that is its own confound, including generational wealth as a significant factor. Third, given their regional dependence and low frequencies, the inclusion of both N264K and *APOL1* in one analysis is problematic. This approach leads to redundancy and collinearity, resulting in uninterpretable coefficients.

We found several potential back-door paths. First, darker skin tone and colorism: regional ancestry often has aspects of physical appearance.

Second, generational wealth: even comparing patients who can all 'pass' as White, Black Americans denied generational wealth had limited opportunities, which the research design did not address (i.e., the problem is more than colorism alone, which also was not addressed).

Third, West African ancestry and the N264K gene: regional distribution of N264K variant, with quite low frequencies (4.3%) in African-American veterans, also likely correlates with physical traits, and because few subjects showed this combination of traits, we do not know whether all combinations truly exist in nature. Further, it could be argued that a more plausible explanation for such an infrequent genetic combination being identified in this sample is that they are simply false positives rather than representing something meaningful.

3.2.5 Equity and APOL1

Roberts noted:

> The issue is not whether genes affect health—of course they do—but whether *genetic difference* explains *racial disparities* in health [132].

The APOL1 mechanism that explains 'racial' differences in KF is unknown [133]. Higher RVs of the *APOL1* gene were identified in all haplotype backgrounds, but the magnitude of their effect was dependent on expression levels. Equity is a confounding factor in all these findings.

'Race' affects COVID outcomes through misdiagnosed lung disease [134,135,136], mismeasured blood oxygen levels [137,138], and inequitable care [139,140,141].

The different 'racial' systems in Brazil and the US converge in colorism. However, because links between 'race', skin color, and ancestry varied under different 'racial' systems, a broader range of physical appearances and SDOH might weaken *APOL1* associations with 'race' in the Brazilian population (i.e., more noise in the data) [142]. Given the wide confidence intervals in the Brazilian data [74] and a general caution with accepting the null hypothesis of no difference, we cannot say the ORs are significantly different when comparing the same risk factors between the two samples, **Fig 10**. However, the remarkably similar ORs between US veterans and Brazilians for a variety of non-genetic covariates support other aspects of personal circumstance as more important than the *APOL1* gene.

Chen et al adjusted for age, sex, and baseline eGFR in a general population study and eliminated correlation between KF and *APOL1* [143]. Grams et al found that 'racial' disparities (e.g., in income and education) explained AKI disparities better than *APOL1* risk genotypes [144]. Grams et al also noted, "…the majority of blacks with the high-risk genotype experience eGFR decline similar to blacks without the high-risk genotype" [145].

3.2.6 Focal segmental glomerulosclerosis

Our re-analyses did not conclude that *APOL1* HR genotype has no effect on AKI and CKD. Hung et al showed that *APOL1* HR genotype modestly increased risk of focal segmental glomerulosclerosis (FSGS) in veterans [75], which is consistent with other recent reports [146,147,148,149], including low penetrance [150], which may depend on cumulative effects of multiple cofactors: "…the development of kidney disease is rare, suggesting the need for a second hit" [151].

Veteran status appears to partially mitigate the FSGS risk, leading to relatively few FSGS and KF events, small absolute percentage rates, and ORs within the block of modest ORs, **Fig 10** and **Fig 11**.

The risk of stereotyping dark skin as a sign of *APOL1* HR genotype follows trans-Atlantic enslavement of West African people (i.e., descendants of formerly enslaved people—both still living in the US and recently immigrated from Caribbean countries). However, mass migration, globalization, and more recent US immigration fueled by military and economic conflicts in Central and East African countries continue to diversify African ancestral histories. Even if the likelihood were increased by visual examination, who and when to test for *APOL1* HR genotype may hinge on understanding reduced disparity in veterans to better inform genetic counseling on prognosis and treatment options [152]. Nonspecific Population Health measures may mitigate accumulated 'second hit(s)' from SDOH—even before any component cofactors are fully characterized.

3.3 Potential implications

Thus far, we have focused on the limitations in the medical literature that can mislead clinical practice by misattributing the mechanisms by which differences appear between racialized groups. The implications of this misattribution extend beyond academics and basic clinical practice. The much larger concern is how this presumption of a biological basis for 'race' shapes medical research and the development of new treatments. The advice of Ioannidis is relevant:

> Before running an experiment, investigators should consider what they believe the chances are that they are testing a true rather than a non-true relationship….

> Corollary 4: The greater the flexibility in designs, definitions, outcomes, and analytical modes in a scientific field, the less likely the research findings are to be true….
>
> Corollary 5: The greater the financial and other interests and prejudices in a scientific field, the less likely the research findings are to be true. [153].

Commercial interests drive innovation, but there is also profit potential in misuse of 'race' [154]. Research into low-cost preventive measures and SDOH usually requires government funding, so we highlight three such areas for further study: **(1)** illiteracy and deprivation cofactors (implied by outcome differences between veterans and the general population), **(2)** role of 'race' when searching for genetic causes without an hypothesis, and **(3)** international collaboration on ethics that could discourage misuse of 'race'.

3.3.1 Proxy for illiteracy and deprivation

(a) Illiteracy

Illiteracy varies by district, **Fig 13**, and may mediate the relationship between 'race' and CKD [155,156], implicating broad consequences of reading failure (e.g., difficulty obtaining jobs with US health benefits that are not universal). Up to 90% of high school graduates may be illiterate [157]. A 2001 summary of decades of reading research funded by the National Institutes of Health (NIH) concluded:

> Failure to develop basic reading skills by age nine predicts a lifetime of illiteracy…. On the other hand, … provision of comprehensive early reading interventions can reduce the percentage of children reading below the basic level in the fourth grade… to six percent or less [158,159].

In contrast, literacy diminished the association between long-term illness and Black 'race' and removed the predictive power of "education" and being African American [160]. Adult literacy programs did not improve CKD [161], but early intervention can succeed [162,163,164,165]. These findings should prompt literacy testing in medical research [166,167] to prevent 'race' from being a proxy for illiteracy and to show whether effective early literacy programs help to eliminate 'racial' health disparities.

(b) Deprivation

Deprivation is associated with CKD [168,169]. The origin of US housing segregation "…has now largely been forgotten" [170,171]. However, patients from disadvantaged neighborhoods, **Fig 14** [172], still suffer health effects of childhood poisonings [173,174,175] and prenatal exposures [176,177] that increase CKD risk [178,179,180]. In *Demolishing Detroit: How Structural Racism Endures*, Caverly noted:

> Racist outcomes without racist intent are the calling cards of structural racism. In the United States and elsewhere, racial disparities in experiences and life chances continue to be relatively unchanged long after racist ideologies and policies have been seemingly rethought [181].

Healthcare access and tracking of serial creatinine may allow early intervention for pre-chronic kidney disease (preCKD) [1]. Further research (e.g., in zip codes of the few White and Black neighborhoods with similar demographics) might show whether early toxic exposures [182] contribute to purported 'racial' disparities in GFR and to the "senile" nephrosclerosis found in one-third of young but absent in 10% of elderly kidney donors [183]. Examining data on KF by zip code [70] may show an effect of veteran status on local 'racial' disparities [25].

3.3.2 Racialized genome-wide associations

Genome-wide association studies (GWASs) often search outcomes data without an hypothesis and often without a known mechanism of action. In a GWAS promoting *APOL1*, Freedman et al noted, "…the genetic risk that was previously attributed to *MYH9* may reside, in part or in whole, in *APOL1*, although more complex models of risk cannot be excluded" [184]. The latter includes stratification of resources based on skin pigment—structural racism.

Structural racism based on pigment (a gene product) may associate the effects of socially constructed environmental insults with single-nucleotide polymorphisms (SNPs) in linkage disequilibrium with pigmentary and other racialized genes [185,186]. Colorism may enhance the illusion of 'race' as biology by varying polygenic scores with polygenic pigment, both directly (e.g., through prenatal and childhood health, education, employment, access) and indirectly (e.g., through circumstances of parents and grandparents), especially confounding GWASs [187]. Further, associations alone cannot tell whether historical violence against groups of people based on appearance induced heritable epigenetic changes in gene function through interactions between social environment and gene expression.

Pigment has physiologic effects (e.g., on pulse oximetry [137,138]) that are not 'racial'(e.g., will not apply to all Black people). However, researchers may consciously or unconsciously engage in visual selection of subjects, typically skewing cohorts of US Black people to those with more pigment and historically harsher experiences (see **Section 3.2 'Race' and genetics**). Neglecting to test an optical device in pigmented people suggests residual exclusion of structural racism.

Instead of combining Black veteran and Black general populations [188,111], GWASs comparing their results might reveal SNPs that appear under racialized socioeconomic and gene-environment stresses (e.g., illiteracy, deprivation).

3.3.3 Appeal to international bioethics

Because 'race' is socially constructed, our research merely confirms well known facts: conclusions of biological 'race' will always be false, and re-analyses will always find social causes. Research providing no explanation for 'racial' differences or no justification for including 'race' beyond "predictive accuracy" is especially problematic.

We briefly discuss legacy commitments that quietly sustain misuse of 'race' through **(a)** data, **(b)** medical journal traditions, and **(c)** international regulatory agreements. We also advocate **(d)** trust through institutional review, which appears crucial to ending misuse of 'race' as an input to healthcare.

(a) Legacy data from pre-ethical 'race'

NASEM noted:

> …studies that are poorly designed to answer research questions are scientifically invalid and unethical…. What is necessary is an understanding of the underlying issues during study design and long before data analyses: the moment of publication is far too late [12].

In 1999, MDRD Kidney researchers proposed the first 'race corrected' eGFR [189]. Their demographic "Form # 04", **Fig 16**, shows "Hispanic" listed under 'race' **(left)** and no instructions under question 10 **(right)** for assigning "Race/Population Group" [190]. In 2006, another MDRD study confirmed the omission consistent with Form # 04: "Ethnicity was assigned by study personnel, without explicit criteria" [191]. In 2021, an unsigned "correction" (22 years after the first study's moment of publication) claimed

MDRD used “self-identified race” [192] but referenced “Screening Form # 03” [193], which lacks any mention of ‘race’.



For DCC Use Only
Rev. 3 12/1/90

E ___
V ___
T ___

Form # 04
Page 1 of 6

MDRD

Modification of Diet in Renal Disease Study
Demographic and Baseline Examination Form

This form is to be completed by the study team at the patient's first clinic visit during baseline.

FORM # 0 4

1. Patient Identification Number ..... ___ ___ ___ ___ ___
2. Patient Name Code ..... ___ ___ ___ ___
3. Clinical Center ..... ___ ___
4. a. Date Primary Informed Consent Form was signed ..... ___ ___/___ ___/___ ___
   b. Has a copy of the consent form been sent to the DCC? (1 = yes, 2 = no) ..... ___
5. a. Date of Patient Visit ..... ___ ___/___ ___/___ ___
   b. Visit Type ..... B
   c. Visit Number ..... 0 0 . 0
6. Referral Source ..... ___
   1 = Self
   2 = Friend
   3 = Outside doctor
   4 = Study doctor
   5 = Other (20 characters maximum) (_____)
   9 = Unknown
7. Has the name and address of a contact person who may know the whereabouts of the patient been recorded? (1 = yes, 2 = no) ..... ___
8. Date of Birth ..... ___ ___/___ ___/___ ___
9. Sex ..... ___
   1 = Male
   2 = Female, able to become pregnant
   3 = Female, not able to become pregnant
10. Race/Population Group ..... ___
   1 = White
   2 = Black
   3 = Hispanic
   4 = Asian
   5 = Native American
   6 = Pacific Islander
   7 = Other (20 characters maximum) (_____)
   9 = Unknown
11. Education ..... ___
   1 = College graduate with professional training
   2 = College graduate
   3 = At least one year of college
   4 = High school graduate
   5 = Completed 10-11 years of school
   6 = Completed 7-9 years of school
   7 = Completed <7 years of school
   9 = Unknown

PWO 1476

2.70

Rev. 4 11/5/90

Form # 04
Page 1 of 3

Modification of Diet in Renal Disease Study
DEMOGRAPHIC AND BASELINE EXAMINATION FORM

This form is to be completed by the study coordinator, physician and dietitian at the initial Baseline Visit (B0).

QUESTION #	INSTRUCTIONS
8.	Enter the patient's birthdate (MM/DD/YY). A complete date must be entered into Datalex. If the day of the month is unknown, enter a 15. If the month is unknown, enter a 06. If year is unknown, enter blank.
9.	It is important that females are determined to be post menopausal or surgically sterile before answering a 3. Menstruating females must have a pregnancy test before all GFR measurements.
12.	Enter the code corresponding to the type of work the patient does. If the patient is not presently working, indicate the code for his or her most recently occupied position. Attached to the instructions is the complete alphabetical list of occupations and their appropriate codes. Enter a 9 if the occupation is unknown. Enter an 8 if the patient has never worked outside the home.
14.e.	Illness refers to any type not just related to renal disease.
16-17.	The following is the list of income categories: 1 = < $7,500 2 = 7,500 - 14,999 3 = 15,000 - 24,999 4 = 25,000 - 39,999 5 = 40,000 - 49,999 6 = 50,000 - 74,999 7 = ≥ 75,000 9 = unknown
21-37.	The study physician should have this form while completing the patient's history and physical exam.
31.	If the patient does not smoke, enter 00.00.
32.	This is in regards only to present smoking. If not presently smoking, enter 00.
35.	The physical exam may be done any time from the Screening Visit to 1 day after the Baseline 0 Visit.

2.41

Fig 16. MDRD Study Form 04 - Demographic & Baseline Exam case report form template (left) and instructions (right). Revised on “12/1/90” (upper left), the “Race/Population Group” (bottom left) is consistent with 1990s requirements. The lack of instruction for ‘race’ (right, question 10) is inconsistent with an early shift to self-identified ‘race’. NIH separated ‘race’ from ethnicity and adopted self-identified ‘race’ in 2001, “EFFECTIVE… January 10, 2002”.

NIH separated ‘race’ from ethnicity and adopted self-identified ‘race’ 11 years after the MDRD forms were last revised [194]. Burke and Corwin commented, “...transition to self-identification of 'race' would have been far ahead of those times and would have required a remarkable degree of empathy, study-related re-education, and… a paper trail” [195]. Lack of response to this timely comment suggests the medical journal editors may not know the identity of the author(s) of the “correction” or that no ethical standards compelled release of the name(s) of the author(s), response to the charge of “faulty recall”, or public debate before altering a 15-year-old text that may have prolonged citations and clinical use of MDRD eGFR despite its then known risks for Black patients:

> When applied to cohorts outside the original study, both the MDRD and CKD-EPI equations have proved to be highly biased, imprecise, and inaccurate when compared to measured GFR [196].

Aware without care

Although studies perpetuate the ‘race’ myth in ways that are “largely unintentional” [197], Hunt and Megyesi found, in 2008, that most genetics researchers **(1)** understood that ‘race’ is invalid, **(2)** used ‘race’ as a proxy for biological cofactors without bothering to explore further (simply assumed cofactors would be difficult to identify and measure), **(3)** could list serious potential negative consequences of misusing ‘race’, but **(4)** did so anyway [198]. After the NASEM report [12], genetics journal editors encouraged the

allowed form of social commentary: genetic scientists rationalizing legacy misuse of socially constructed 'race' [199,200,201,202,203] to continue publishing BS under "…the tranquilizing drug of gradualism" [204]. Their predecessors did the same, 75 years ago:

> For the social scientists gathered by UNESCO to write its 1950 'Statement against race and racial prejudice', race had to be disproved on scientific grounds, a task which they saw as easily achievable. The Statement claimed that:
>
> > The division of the human species into 'races' is partly conventional and partly arbitrary and does not imply any hierarchy whatsoever. Many anthropologists stress the importance of human variation, but believe that 'racial' divisions have limited scientific interest and may even carry the risk of inviting abusive generalization. (UNESCO, 1968: 270)
>
> Directly after the publication of the Statement, it was followed by an alternative Statement written mainly by geneticists also involved in the UNESCO project…. that race continued to be of scientific usefulness for describing 'groups of mankind possessing well-developed and primarily heritable physical differences from other groups' (Comas, 1961: 304) and should not be confused with politics [205].

Healthcare vs research

As editor-in-chief of *The New England Journal of Medicine* (NEJM), Relman included kidney dialysis in his 1980 warning against "the medical-industrial complex" [206]. Kassirer (a nephrologist and former editor-in-chief of NEJM) and Steinbrook (a former editor at NEJM) recently restated "…the necessity of ensuring that the interests of the public come before those of stockholders" and noted:

> Standing up for patients… is public service, not a partisan political activity [207].

MEDICAL ETHICIST EVELYNE SHUSTER described "…the continuing difficulty physician–researchers have with accepting public regulation of research" and the ethical lapses of US doctors testifying at the Nuremberg Medical Trial that inspired

> …moral rules centered on the participant and not on the physician….
>
> Ivy repeatedly said that he relied on Hippocratic ethics, which govern the doctor–patient relationship. In the end, however, he folded, undermining his entire testimony…. He had to admit that there were differences between a treating physician who acts in his patients' best interests and a physician–investigator whose goal is to test a scientific hypothesis for the benefit of society rather than the participant [208].

Research governance "for the benefit of society" [209,210] has allowed misuse of the contributions of Black participants to worsen healthcare for Black patients [34,61]. **MEDICAL ETHICIST HARRIET A. WASHINGTON** documented ongoing ethical lapses of medical research in *Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present* [211]:

> Today, the worst abuses are mostly memories, although some forms of abusive research persist, and a few new ones have arisen…. The long history of flawed science in the service of preconceived notions is being supplemented by new, insufficiently questioned racial theories of disease. Adopting these unquestioningly while ignoring important environmental disease factors not only imperils black health; it also reinforces the idea of blacks as possessing dramatic physiologic differences…. [211].

(b) Legacy traditions of US medical publishing

The origins of US medical publishing offer insights. The American Medical Association (AMA) described the determination of its founder:

> …to explicitly exclude women and Black physicians…. [His] role was highly active, not passive, and his choice for a racist direction was pursued with energy and force [212,213].

In 1880, as founding editor of *The Journal of the American Medical Association* (JAMA—"the most important US journal in the first half of the 20th century" [214]), this racist man established the traditions of medical publishing that keep medical research inside the grey oval, **Fig 15,** blocking study of the role of 'race' in research findings. Like other journals that rejected our claim of relevance (e.g., to discuss the role of illiteracy and sociology of deprivation in our research), JAMA is known for excluding discussion of the racism behind socially constructed 'race' and for shunting consideration of social cofactors to "Commentary" and "Perspective" [64].

Recounting the antebellum 'racial' theorizing of a founder of *The New England Journal of Medicine*, **MEDICAL ETHICIST CHRISTOPHER D.E. WILLOUGHBY** et al noted:

> Leading journals published debates over whether Black people and White people were different species. As they built enduring U.S. medical institutions, largely improving medical knowledge and practice and standardizing training, they wove racist theories and norms into the fabric of American medicine.
>
> Understanding racism in American medicine requires scrutinizing not only the most extreme beliefs and behaviors but also everyday practices and routines. For centuries, physicians normalized racist ideas…. Reversing this long historical process requires more than just reaction or reckoning: it will require complex work to fully disentangle racial thinking from medicine [215,216,217].

Editors with a different experience of 'race' could enhance "peer review" of 'race' in medical research, but decent, well-meaning colleagues who edit medical journals are overwhelmingly 'not Black' [218]. Blind spots allowed the misuses of 'race' we noted above, suggesting the philosophy of human medical science needs reexamination [219,220,221,222,223]. And because advocating change takes more words than "stay the course", modern word, figure, and reference limits also favor the status quo (i.e., "…the master's tools will never dismantle the master's house" [224]).

(c) Pharmaceuticals "harmonizing" 'race'

The Minority Health and Health Disparities Research and Education Act of 2000 required collection of 'racial' data that facilitated the "pharmaceuticalization of race" [225]. **MEDICAL ETHICIST SHAI MULINARI** et al found sharply increased 'race' and ethnicity data on drug labels that encourage 'racialized' perceptions in medical care:

> …in 2004–2007, 46% (37/81) of US labels contained race/ethnicity demographic information… versus 80% (171/213) in our 2014–2018 sample… the routine report of race/ethnicity demographics and analyses may prime prescribers to believe that race and ethnicity are biologically and therapeutically meaningful *even* when labels suggest no differences and particularly when they assert minor or ambiguous differences [226].

BiDil was the FDA's first 'race'-based drug. **MEDICAL ETHICIST JONATHAN KAHN** described the utility in marketing misuse of 'race':

> Medical researchers may say they are using race as a surrogate to target biology in drug development, but corporations are using biology as a surrogate to target race in drug marketing…. It is far easier to target African Americans than to identify a market of particular individuals who happen to respond well to BiDil because of their genetic makeup regardless of race [154].

ETHICIST MULINARI et al summarized the history:

> …much empirical and theoretical work has focused on BiDil, but the European Medicines Agency (EMA) never approved this drug….

> …the ICH-E5 document, "Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data"…. was developed by regulators and industry in the EU, the USA, and Japan… as part of an effort to harmonize requirements for drug development and regulation under the auspices of the International Conference on Harmonization (ICH)…. The EU did not want to "overemphasize diversity" between races; the USA wanted to consider race a potentially important variable, but "hoped [that] the US [racial and ethnic] standards would be accepted as universal"; and Japan emphasized that the uniqueness of its population meant that the Japanese could not be subsumed under a diverse "Asian race,"…. Despite the reported little EU interest and opposition from Japan, the final ICH-E5 document suggested that difference could be gauged at the level of three "major racial groups," i.e., Asians, Blacks, and Caucasians [226].

'Race' persists through active institutional maintenance [227]. "Self-identification" of 'race' projects a veneer of legitimacy, but victims of shared hardship must "choose" their affiliation from a constrained, globally "harmonized" list curated by the US Food and Drug Administration (FDA). **MEDICAL ETHICISTS SHAI MULLINARI AND ANNA BREDSTRÖM** described the "collaborative" international regulation that reinforces US 'racial' categories:

> The CDISC [Clinical Data Interchange Standards Consortium]… defines race as 'an arbitrary classification based on physical characteristics' and endorses the use of the FDA-requested racial categories… either using a direct question (i.e. 'Which of the following five racial designations best describes you?') or indirectly using 'expanded categories' such as Arab or White South American that are 'collapsible' into the US categories, such as White…. translating this race-based data into regulatory and academic science that stabilise the idea of race as a key biomedical variable [228].

ETHICIST WASHINGTON described pharmaceutical industry infiltration of medical journals for the exploitation of 'racial' categories through:

> …the much-abused technique of 'data mining,' wherein small subgroups of an unsuccessful trial are relentlessly scrutinized in search of groups for whom a benefit emerges, or seems to [229].

The current US drug approval process does not ensure effectiveness, sometimes approving expensive "…tokens of healing as a cultural process" that are propelled by direct-to-consumer advertising until therapeutic failure is slowly demonstrated over years of use by the general population [230]. **MEDICAL ETHICIST EZEKIEL J. EMANUEL** noted that the FDA also approves drugs under an alternative, fast-track pathway that compares efficacy to no treatment (i.e., placebo or nothing), allowing "…interventions that are not ineffective, but offer minimal benefits for their cost" [231] (see **Appendix: 5.3 Pharmaceutical pricing**).

"Harmonizing" dialysis

The EU accepts globalized regulations that lend international credibility to US promotion of biological 'race' [232], suggesting European firms and researchers might profit indirectly from racialization of US healthcare. European governments forbid or reject use of 'race' at home [12], but allowed representatives from the US to prevail in prioritizing 'racial' differences at an International Conference of Harmonization (ICH) [233]:

> Thus, ethnic sensitivity is due to "ethnic factors"… either "intrinsic" or "extrinsic", and in the ICH definition, race is solely "intrinsic", and more specifically *genetic* [81].

Two years after NASEM recommended against using 'race' "…as a proxy for human genetic variation…. whether self-identified or not" [12], two groups of authors recently called for a new form of "harmonization" of 'race', writing in the *Journal of the American Heart Association*, "…to update recommended categories for global relevance… to

improve the collection of race and ethnicity data in clinical trials" [234], and in *JAMA Psychiatry*, "…that differences in reporting race and ethnicity across geographic locations… highlight the need for international guidelines to ensure equitable recruitment and reporting in clinical trials" [235]. Companies funding these authors include (among others) AstraZeneca, a Swedish-British company evaluating a drug for CKD associated with *APOL1*, and CSL Vifor Fresenius, a Swiss-German company.

In the US, two companies provide 80% of dialysis services: Fresenius and Davita, a US company. Fresenius derives twice the revenue from a patient in North America than under price controls in Europe, **Fig 17** [236]. The US government guarantees payment for kidney care [237] and thus appears to subsidize universal healthcare in Europe by paying double for the same service.



Fig 17. Fresenius reported marked differences in revenue per treatment across various regions (2019).

Diamonds and dialysis extract enormous wealth from the US and Japan, even though the former lack any intrinsic value [238]. Kidney care warrants a premium for superior outcomes, but outcomes are poor in the US, **Fig 1**. The dialysis industry influences policy to preserve profit [239,240,241], but the costly care is inferior:

> Taxpayers spend more than $20 billion a year to care for those on dialysis—about $77,000 per patient, more, by some accounts, than any other nation. Yet the United States continues to have one of the industrialized world's highest mortality rates for dialysis care…. At clinics from coast to coast, patients commonly receive treatment in settings that are unsanitary and prone to perilous lapses in care…. Meanwhile, the two corporate chains that dominate the dialysis-care system are consistently profitable, together making about $2 billion in operating profits a year.
>
> One reason the system's problems have evolved out of the health care spotlight is that kidney failure disproportionately afflicts minorities and the dispossessed…. [242].

Persistent AMA opposition made the US the only rich nation without some form of universal healthcare [243]. And although medical care is different from other services, no distinction was recognized in the broader US philosophy that Kuttner described in *The New York Review of Books*: the shift from trust in government to trust in for-profit businesses:

> …a succession of Democratic presidents joined Republicans in turning away from the New Deal model of regulated capitalism toward what has come to be known as neoliberalism…. that markets work efficiently and that government attempts to constrain them via regulation and public spending invariably fail, backfire, or are corrupted by politics. As public policy, neoliberalism has relied on deregulation, privatization, weakened trade unions, less progressive taxation, and new trade rules to reduce the capacity of national governments to manage capitalism [244].

(d) Trust and institutional review

Finally, institutional review could invoke ethics to help end the misuse of 'race' fueled by widespread conflicts of interest (COI) [245]. Until recently, research on trust in the context of US healthcare primarily focused on "…trust issues related to systemic racism and health equity" [246]. Although a medical trope suggests that persuading Black patients to trust healthcare will reduce 'racial' disparities, Warren et al acknowledged:

> …the deep and justified lack of trust that many Black Americans have for the health care system in general and clinical research in particular.… It would be wrong, as well as ineffective, to ask Black communities to simply be more trusting [104].

More recently, an inversely u-shaped association appeared between health literacy and trust—more trust at medium health literacy and less at low and high health literacy [247].

Black people aware of the long history of abuse in US healthcare have one form of high health literacy. However, the system can discourage legitimate concerns [248]. **ETHICIST WASHINGTON** noted:

> …commentators have made Tuskegee an overburdened icon, suggesting that Black Americans are overreacting to a single study rather than to consistent abuse in the U.S. healthcare system [249].

A more traditional form of high health literacy also supports ethical review, coming from those at the pinnacle of academic medicine.

Conflicts of interest

Three consecutive Editors-in-Chief of *The New England Journal of Medicine*—Arnold S. Relman, Jerome P. Kassirer, and Marcia Angell—linked doubts about medical research to COI. In 1980, Relman suggested that organized medicine should "…act decisively in separating physicians from the commercial exploitation of health care" to preserve its "moral authority with the public and the government" [206]. In 2002, Relman and Angell described the extent of pharmaceutical industry influence:

> It has also… assumed a role in directing medical treatment, clinical research, and physician education that is totally inappropriate for a profit-driven industry…. prescription drugs are not like ordinary goods, and the market for drugs is not like other markets [288,250].

In 2015, a series of articles in *The New England Journal of Medicine* "…questioned whether the conflict of interest movement has gone too far in its campaign to stop the drug industry influencing the medical profession," and Steinbrook, Kassirer, and Angell responded: "The problem, obviously, is that their objectivity might be compromised, either consciously or unconsciously, and there would be no easy way to know whether it had been" [251]. In 2016, Angell added, "Unless bias is blatant, there is simply no sure way to tell", so we expect conflicted judges to recuse themselves, and we do not permit conflicted journalists to write the story: "Why should it be different for medical researchers?" [252].

The Strategic Council for Research Excellence, Integrity, and Trust of the National Academies expressed concern that: "Current processes for declaring an author's relationships that might be viewed as potentially impacting his or her ability to address an issue without bias* are cumbersome, uneven, and inefficient" [253], suggesting belief that one can be aware of one's own bias, declare it, and then be truthful. Streamlining COI *disclosure* misses the mark in a world of monetized medical research and publishing. COI declarations (often buried on journal websites, even for print editions)

shift the burden of discerning truth from publishers with the leverage to ask questions and require compliance to reporters and readers.

Kassirer noted, "…the vast attention paid to failure to disclose is misplaced… more attention must be focused on the financial conflicts themselves and their consequences" [254]. **MEDICAL ETHICISTS JOEL LEXCHIN AND ADRIANE FUGH-BERMAN** explained the real-world result:

> "Disclosure of a conflict of interest, paradoxically, increases trust in the speaker, who is now viewed as an honest, forthright person…. Disclosure may lull audiences into believing, wrongly, that they can extract unbiased information from a biased presenter" [255].

Almost two-thirds of panelists developing clinical practice guidelines for kidney disease had financial COI [256]. Despite professional standards that editors, guest editors, and their staff should publish disclosure statements about their COIs, very few bothered to do so [257]. "Seventy-two senators and 302 members of the House of Representatives cashed a check from the pharmaceutical industry ahead of the 2020 election" [258].

When opioid deaths drew attention, congressional investigation found opioid money had compromised "…health professionals, patient advocacy groups, medical professional societies, research universities, teaching hospitals, public health agencies, policymakers, and legislators…" creating the opioid crisis [259,260]. Annual opioid sales peaked at $8 billion (in 2015) [261]. Federal spending on kidney disease *increased* by $5 billion *annually* from 2015 to 2019.

When FDA approval of a drug rejected by outside experts drew attention, congressional investigation found FDA violated its own policies by collaborating on the company's drug application and found internal company documents showing the company targeted physicians, patient advocacy groups, and other avenues to gain influence to have those groups apply pressure for FDA approval (as done by the opioid industry), while simultaneously seeking exemption from the Anti-Kickback Statute [262,263]. Unrelated to this drug, the company later offered $900 million to settle allegations of kickbacks to doctors in other areas [264,265].

A recent article promoted eGFR for early detection of kidney disease [266] despite unacceptably high eGFR false positive results above 60 mL/min that favor diagnosis using serum creatinine [1,267]. Its authors declared "…no conflict of interest to report in relation to the topic of this study", but several indicated funding from AstraZeneca and Fresenius, two European companies that would be affected by reliable early diagnosis of CKD.

This is not to name a handful of bad actors but an example of an underlying pattern. There is financial incentive for healthcare businesses to help researchers continue work that enables their business interests, so they redirect some of that wealth. Even without owning shares in a healthcare corporation (i.e., no direct gain from rising stock price), researchers with no current relationship to industry may hope that future funding will keep them employed. Such influence is not captured on a COI form.

European industries extract wealth from 'racialized' US patients in ways their own governments forbid (e.g., misuse of 'race' in drug approvals [3,226]) or regulate (e.g., drug prices) to provide universal healthcare that the US does not [13]. International reviewers may understand, consciously or unconsciously, that they benefit from US structural racism. A European reviewer funded by CSL Vifor Fresenius withdrew support for our preCKD manuscript after revisions he requested explored ethics of 'race' and COI (see Comments to our preCKD manuscript [1]).

In *The New York Review of Books*, Angell described the effects of industry-funding in peer-reviewed research:

> Because drug companies insist as a condition of providing funding that they be intimately involved in all aspects of the research they sponsor, they can easily introduce bias in order to make their drugs look better and safer than they are…. In short, it is often possible to make clinical trials come out pretty much any way you want, which is why it's so important that investigators be truly disinterested in the outcome of their work….
>
> Conflicts of interest affect more than research. They also directly shape the way medicine is practiced, through their influence on practice guidelines issued by professional and governmental bodies, and through their effects on FDA decisions….
>
> In recent years, drug companies have perfected a new and highly effective method to expand their markets. Instead of promoting drugs to treat diseases, they have begun to promote diseases to fit their drugs. The strategy is to convince as many people as possible (along with their doctors, of course) that they have medical conditions that require long-term drug treatment. Sometimes called "disease-mongering," this is a focus of two new books: Melody Petersen's *Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs* and Christopher Lane's *Shyness: How Normal Behavior Became a Sickness*.
>
> To promote new or exaggerated conditions, companies give them serious-sounding names [e.g., "brain fog", "the kidney-failure gene"]….
>
> It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of *The New England Journal of Medicine* [268,269].

Richard Horton, Editor-in-Chief of *The Lancet*, summarized:

> The case against science is straightforward: much of the scientific literature, perhaps half, may simply be untrue. Afflicted by studies with small sample sizes, tiny effects, invalid exploratory analyses, and flagrant conflicts of interest, together with an obsession for pursuing fashionable trends of dubious importance, science has taken a turn towards darkness [270].

The task is daunting, but for clinicians who no longer know what to believe, **ETHICIST WASHINGTON** suggested resources:

> Several books offer clear, impeccably researched guides to sniffing out manipulation. Angell's *The Truth About the Drug Companies* and Abramson's *Overdosed America* are likely to be most helpful to a busy clinician. The PharmedOut website offers tools for detecting undue influence in medical research and publishing [229].

Institutional review

It is a fair question whether collecting 'race' is worth the risks, or whether those risks can be avoided by introducing ethical regulatory oversight. **MEDICAL ETHICISTS RAYMOND G. DE VRIES AND SCOTT Y. H. KIM** offered hope at the intersection of sociology and bioethics:

> The collaborative work that gets done under the rubric of empirical bioethics moves the important ideas of philosophical bioethics into the real world of medicine and medical research where human beings live and work, and help and harm each other [271].

Institutional review boards (IRBs) could challenge misuse of 'race' under existing regulations protecting those "…vulnerable to coercion or undue influence" [272,273,274,275]. However, recent developments risk weakening ethical oversight. In 2017, NIH adopted a single IRB (sIRB) model and eliminated local IRBs from multi-

center trials, prompting Ervin, MEDICAL ETHICIST HOLLY A. TAYLOR, et al to caution, "We do not yet know whether streamlining IRB review will affect an IRB's ability to protect the welfare of human participants" [276] (see **Appendix: 5.4 'Race', risk, and novel research**). And although commercial and non-profit IRBs are both susceptible to COI, and how to regulate them is debatable [277], MEDICAL ETHICIST ARTHUR L. CAPLAN noted:

> "This shift to commercial IRBs is, in effect, over," said Caplan, who heads the division of bioethics at New York University Langone Medical Center…. Commercial IRBs now oversee an estimated 70 percent of US clinical trials…. with larger IRBs buying smaller ones, and even private equity firms coming along and buying the companies…. which often have harder-to-spot conflicts of interest and a profit motive [278].

Summary

Our research confirms that equal outcomes should be expected under equal conditions regardless of 'race'. We discussed how 'race' is misused, manipulated, and selectively included or omitted. We described international 'racial' inconsistencies, which are internalized from childhood experiences, and gave examples of medical researchers consciously and unconsciously spreading the myth of 'race' and that Black people rationally distrust medicine and medical research. Given FDA regulations promoting 'race' and the power asymmetry between subject communities and the pharmaceutical industry, it seems unlikely that collaboration alone [279] will temper the profit motive in misuse of 'race'.

American bioethics favors autonomy almost to the exclusion of its other three founding principles, but as MEDICAL ETHICIST JOSEPH J. FINS noted, we should "…move beyond narrow questions of patient choice, particularly when the disenfranchised are not in a position to exercise that choice" [280]. Fins added, "…that while rights are necessary to avoid exploitation, they are not sufficient and that instead there should be a focus on capabilities that promote human flourishing" [personal comm]. In this case, it is about identifying nascent kidney disease with metrics that are accurate and accountable to scientific and ethical norms [1,12]. Further research might show whether an appeal to international bioethics could end misuse of 'race' in medical research.

4. CONCLUSION

Re-analysis of 'race' reveals cross-cultural conflicts in its social origins such that research associating socially constructed 'race' with any explanation other than structural racism will always be wrong.

Selection and training of servicemembers create comparable starting conditions for veterans. Those in Veterans Administration Healthcare showed comparable social determinants of health and comparable kidney outcomes, which should be the expected norm for all under more equal social conditions—regardless of socially constructed 'race', ethnicity, or nationality. Further research to identify essential veteran cofactors may improve general population health, reduce 'racial' disparities, and redirect some resources to prevention.

Apolipoprotein L1 high-risk variants increase focal segmental glomerulosclerosis, but the increased risk appears too small to justify treatment at the population level. Broad application of nonspecific Population Health measures may further mitigate risk.

Conflicts of interest, single IRBs, and novel research warrant review of the assumptions in ethical oversight.

Despite scholarly consensus and 100 years of academic articles that biological 'race' is scientifically invalid, misuse persists in medical research, suggesting, for further study, we may need to **(1)** work together, **(2)** discourage standing in the doorway, and **(3)** appeal to principles of international bioethics to end misuse of 'race'.

5. APPENDIX

5.1 Ethics statement

'Race' in research: NASEM advised, "Researchers should be as transparent as possible about the specific procedures used to name groups within their data sets" [12]. We did not present 'race' as an input to clinical decisions, a means of stratifying care, or an hypothesis for genetic difference without data. One primary source used 'race' designated in Medicare Denominator File or VA data sources [70]. We explored the approach to 'race' and ancestry in the other primary sources (see **Discussion**).

Human subjects: The primary sources used information collected for non-research activities in VA Healthcare or obtained informed consent from all participants after receiving IRB approval. Secondary re-analysis of publicly available data is not considered human subjects research and is exempt from review [281].

Privacy: The study included no individually identifiable patient health information.

5.2 Re-analyses

Our main hypothesis is that because 'race' is socially constructed, social context and social cofactors will remove or explain 'racial' differences in CKD and KF. A corollary is that re-analyzing studies that endorse biological 'race' will always be fruitful. During recent questioning of eGFR 'race corrections', our preliminary re-analysis of a study of KF in Black and White veterans elicited responses referencing *APOL1* (e.g., "the kidney failure gene") as "validating" 'racial' difference in kidney disease. We broadened our literature search.

Relevant to our hypothesis, we searched PubMed (on February 24, 2024) for titles or abstracts that included "veteran" and "APOL1", yielding four studies [282,71,75,188]. Of three studies directly addressing kidney disease, we added re-analysis of two (**Sections 2.2 and 2.3**) and noted the third in Potential Implication for GWASs (**Section 3.3.2**). We selected these articles because they represented an emerging program of research on the genetic underpinnings of 'race' and kidney disease. While it may not represent all studies on this topic, the goal was to illustratively characterize how the body of literature may support the myth of 'race' as biology.

Our secondary re-analyses involved extracting primary data of veterans from previously published tables and figures (i.e., data of all subjects in two of the studies and 80% of subjects in the third), using knowledge of socially constructed 'race' and obvious social cofactors to reorganize the data into simple, accessible graphs and charts to better compare RRs and ORs of CKD rates and KF outcomes.

5.2.1 Re: Removing 'race correction'

The large study of KF in veterans by Choi et al [70] presented enough data to reverse the eGFR 'race correction' (**Section 2.1**). We repurposed data from its first and second tables, removed 'race correction' by dividing MDRD eGFRs by 1.21, and examined eGFR prevalence and rates of KF against eGFR results with and without 'race correction'. Mathematically, transforming a variable by a constant has a one-to-

one impact on the magnitude of the regression coefficient [283], and the estimated association will change proportional to that number, which may be useful if an actual difference could be overlooked. However, if no true 'racial' difference exists, the association between eGFR prevalence rates and KF rates for White and Black patients should be similar, and 'race correction' would inflate the association's magnitude, implying more KF than found.

We estimated the association among White patients, Black patients with unadjusted eGFR rates, and the same Black patients with eGFR 'race correction' removed, hypothesizing that the ratio of associations for 'race-corrected' data and 'not-race-corrected' data would equal 1.21, the exact magnitude of 'race correction'. Additionally, we hypothesized that there would not be a significant difference in associations between White and Black patients after removing 'race correction'.

5.2.2 Re: Veterans and APOL1

Re: *APOL1*, AKI, and COVID: We re-analyzed a study by Hung et al [71], calculating RR and OR from primary data in their first and second tables. Although we dismissed this article in an early version of this manuscript (due to uneven distribution of vasopressors and mechanical ventilation between those with and without AKI), repeated encounters with references to it as "proof" that genetic susceptibility causes 'racial' disparity prompted our full re-analysis and PubMed search.

We adjusted the *APOL1* RR to remove the confounding of high-impact cofactors. For comparison, we included a similar study in the Brazilian general population [74], where 'race' is defined differently. Because some CIs were unusually asymmetric, we recalculated them from the given p values and z-statistics.

Re: *APOL1* and N264K: We similarly re-analyzed another study by Hung et al [75] that examined associations between *APOL1* LR and HR genotypes, N264K variants, and the US taxonomy of socially constructed 'race'. We focused on the data from US veterans (the bulk of their data) and created simple graphs to better show the relationships within the data. Because N264K**+** is an *APOL1* variant more common in Europe (occurring in less than 5% of US Black veterans), we further narrowed to the 95% of Black veterans without N264K, calculating and ordering results by ORs between the LR and HR (N264K**-**) subgroups.

5.3 Pharmaceutical pricing

Most countries regulate the price of medicines, but US drug companies may charge whatever the market will accept [284,285]. Extreme pricing makes the US market the most lucrative in the world, as ETHICIST EMANUEL noted:

> The whole world spends about $1 trillion on drugs, and roughly half of that is spent in the U.S. We're less than 5 percent of the world's population, and yet we pay 50 percent of drug costs [286].

For example, the FDA approved semaglutide (Ozempic, Wegovy) for type-2 diabetes, then weight loss. The estimated production cost of $193 to 380 per person-year is a small fraction of "…branded semaglutide—$6,936-7,716 per person-year (ppy) for oral semaglutide… in the USA, prior to recent price increases of… 3.5% in 2025" [287]. In 2002, Relman and Angell noted:

> The ten American pharmaceutical companies in the Fortune 500 list last year ranked far above all other American industries in average net return, whether as a percentage of revenues (18.5 percent), of assets (16.3 percent), or of shareholders' equity (33.2 percent). (For comparison, the median net return for other industries was only 3.3 percent of revenues.) [288].

The pharmaceutical industry replaced pricing from costs and markups with pricing from the estimated value of a human life saved [289,290]. The latter takes responsibility for bundled services. Drugs do not administer themselves but require support services. These include drug delivery systems, medical and nursing staff, health facilities, primary care, food, housing, and "public health and social measures" [291]. If not bundling for healthcare efficiency [292], then other vendors can charge repeatedly for the same life. If bundled pricing, then not providing associated services is unbundling [293].

5.4 'Race', risk, and novel research

New research methods expose all patients to ethical lapses, including Black patients overrepresented in dialysis centers and emergency rooms—the last resort for uninsured people. In this section, we discuss the ethical limitations of including 'race' in the process of doing research.

5.4.1 Eroding informed consent

ETHICIST WASHINGTON described the gradual erosion of the first principle of the Nuremberg Code, informed consent:

> …researchers bypassed eliciting subjects' consent by obtaining waivers of informed consent for studies on a case-by-case basis. Then a 1996 law… provided a waiver for certain types of medical research said to carry only "minimal risk." …
>
> …another 1996 change in the Federal Code of Regulations: withholding informed consent from unconscious trauma victims….
>
> This approach is an ethical error. If a person (or her legally appointed representative) cannot give consent, she should be treated with duly tested standard care as if there were no experiment to worry about [249].

Pragmatic clinical trials (PCTs) or cluster randomized trials (i.e., on clusters of populations served by distinct clinics or hospitals) raise novel ethical issues [294]. The fact of a study may be obscured to the subjects by blanket waiver of informed consent when the IRB finds "minimal risk" and that the waiver does not "adversely affect the rights or welfare of the participant" [295]. Disagreement between "risk-averse" and "permissive" IRBs on multi-site studies is avoided by allowing only one review, by a possibly remote sIRB, and approval may seem justified if the subjects experience "a minor increase over minimal risk" [296]. However, because the determination of "minimal risk" by either type of IRB might be incomplete, another approach is to require dialogue among IRBs representing their local populations, aiming to understand and resolve any fact-dependent disagreements among their experts [297].

In a study of attitudes toward PCTs of maintenance dialysis in patients with kidney failure, subjects and their partners preferred to be given the choice before engaging in such studies, even anticipating loss of trust if the study was not openly declared [298]. It is unclear whether "therapeutic illusion"—belief that a study is done to benefit the subjects rather than future populations—may confound findings that a "substantial" minority of patients might accept a hypothetical study done without written consent [299]. Some ethicists questioned the lack of public oversight of such studies [300] and the creeping application of waiver of consent to studies manipulated to fit into waiver criteria [301], undermining autonomy of patients and clinicians alike. Even "stakeholders" saw "…ethical challenges in four domains", as Kalkman et al noted:

> (1) less controlled conditions creating safety concerns, (2) comparison with suboptimal usual care compromising clinical equipoise, (3) tailored or waivers of informed consent infringing patient

> autonomy, and (4) minimal interference with real-world practice reducing the knowledge value of the results. [302].

5.4.2 Declining physician autonomy and community influence

Clinician autonomy affects trustworthiness [303,304]. Most clinicians have now ceded their autonomy to corporate interests [305] and the well-intentioned corporate impulse to stifle dissent [306]. Clinicians are expected to see more patients in less time, at lower cost, with better outcomes, under greater oversight, and at higher patient satisfaction [307], while inundated with medical literature they cannot trust and admonished to "Get With The Guidelines" [308]. The drive to reduce costs by shortening hospital stays favors hospitalists—clinicians employed by hospitals to efficiently manage inpatient care. With primary care clinicians no longer following their patients into the hospital, many left the hospital medical staff, severing a link between the community and inpatient care. House officers are supervised by hospitalists, but clinical review by an attending physician who knew the patient outside the hospital ended a decade ago. Furthermore, medical researchers may differ from clinicians dedicated primarily to patient care. The declining influence of community physicians and loss of independent voices on the medical staff erodes an informal layer of ethical review, reducing communication between hospital and community that is a crucial consideration for PCTs [309], particularly when a possibly remote sIRB might declare "minimal risk" or "a minor increase over minimal risk" that allows blanket waiver of informed consent.

5.4.3 Shifting IRB review

Because ethicists can disagree, seemingly redundant review by IRBs at several sites can improve understanding of risks and ethical quandaries, such as definition of "minimal risk" [294,295,296,297]. Nevertheless, without legislative input by the US Congress or executive input by the Office of Civil Rights, government scientists loosened their own oversight rules and mandated a sIRB for multi-site human subjects research, which favors commercial IRBs. **MEDICAL ETHICIST GEORGE J. ANNAS** noted the significance of IRB review:

> Although IRB review was not required by the Nuremberg Code… doing away with the requirement for all but 1 institution involved in a multicenter research trial could gut the review requirement of any real meaning…. because the structure of the regulations requires holding the individual institution "responsible for safeguarding the rights and welfare of human subjects." … The single IRB requirement risks replacing ethics with efficiency….
>
> Under existing regulations, all members of an IRB but 1 could have an inherent conflict of interest because they can be employed by or affiliated with the institution. [310].

We examined 270 pages of public comments on the proposed (now implemented) NIH policy requiring a sIRB for multi-site studies [311]. The medical research community offered many enthusiastic comments, anticipating improved research efficiency. **Fig 18a** and **Fig 18b** show some concerns expressed in public comments before the sIRB mandate (note especially comments 39, 42, 116, 133, and 167).

Selected ethical concerns raised before NIH single-IRB mandate (2017)		
#	Commenter	Excerpt
39	Medical ethicist Evelyne Shuster, PhD	...single Institutional Review Boards will eliminate the benefits of local IRB, having what is needed for a complete and thorough protocol review within reach, and whose members are presumed to reflect the values of the community, and therefore the values of subjects themselves who are drawn from that community.
42	Curtis Meinert, Professor The Johns Hopkins Bloomberg School of Public Health Department of Epidemiology	The proposers argue that the single IRB model may lead to enhanced protections by "minimizing institutional conflicts of interest". As a researcher I am more interested in balance of conflicts than in minimizing them. There is information in the different philosophies and points of views of individual IRBs that, in all likelihood, add to protections.... There is no doubt that the existing IRB system is cumbersome and needs revision but that should be accomplished by legislation rather than by administrative fiat....
67	James Feldman, MD, MPH, FACEP	The major problem with multiple IRB reviews for multicenter studies was that there was no procedure for reconciling discordant reviews or providing some kind of analysis where there were differences as to whether these differences were substantive. The human subject regulations recognize the role of robust discussion by requiring that minutes of IRB meetings summarize "controverted issues and their resolution" 45CFR46.115(a).... there is no assurance that a single center might not make serious errors in its review of a study.
78	Steering Committee, The Study of Women's Health Across the Nation	In our experience with... a multi-site longitudinal observational cohort study... the recruitment and retention strategies had to vary across the sites because each involved a distinct population of racial/ethnic groups and communities....
94	Harry W. Orf, PhD, Senior Vice President for Research Massachusetts General Hospital	The Draft Policy describes in general the requisite responsibilities for both the reviewing SIRB and the relying institutions. But it fails to recognize how different types of studies require vastly different logistics and resources for both the SIRB and the relying institution. Due to these differences, there are multi-site studies that fit more easily into an SIRB approach and there are others that do not....
102	The University of Florida	Even with a single IRB, each participating institution on a project would need to retain certain mandatory local responsibilities, including monitoring of compliance, response to adverse incidents and breaches; application of state law requirements and local standards of care, etc... Only a local institution will know its investigators' capabilities and reliability for certain types of responsibilities, which is critical factor in developing appropriate protocols.... IRBs gain the full breadth of detailed factual and contextual information about the research project, the investigators and the subjects, that no other single body at the institution usually has....
106	Human Subjects Protection Branch Walter Reed Army Institute of Research	4. No data are provided to address how safety of subjects will or will not be impacted by this policy. The Policy simply states that there is no evidence that multiple IRB reviews better protect subjects. On the other hand, there is no converse evidence that multiple IRB reviews do not.... 9. This policy takes "institutional" out of IRB. This promotes the use of central, fee for service (for profit) IRBs. The policy states that ..."If this approach is taken, the participating site should expect to bear the cost of the additional review." Aren't they already doing so, unless fee for service IRB is in play?
110	Jeffrey H. Silverstein, MD, MS, AGSF, Executive Director, Program for the Protection of Human Subjects, Senior Associate Dean for Research, Icahn School of Medicine	Applicability: The idea of a central or single IRB for multi-site research is extremely valuable and useful in circumstances such as NeuroNExt and StrokeNet in which a network is established with the idea of conducting multiple multi-site projects. The experience with both of these entities is that the upfront effort required to establish the central IRB structure is extensive, time consuming and expensive. This effort has a significant return on investment once established. However, the idea that every single multi-center study will benefit from this type of central organization is not supported by current experience....
116	Ann M. Arvin, MD, Vice Provost and Dean of Research, Penelope Eckert, PhD, Chair IRB 2, David Oakes, MD, Chair, IRBs 1, 6, and 8, et al Stanford University	The proposed policy indicates that **"...a duplicate IRB review at a participating site would be counter to the intent and goal of the policy".** However, it would not be possible to comply with this policy and "...be responsible for meeting other regulatory obligations... without performing a local review. We believe that no NIH mandate can or should relieve participating institutions from their fundamental obligation to protect human subjects involved in their research. At the same time, it is unreasonable to require the institution to undertake liability for the proper execution of this responsibility without performing the requisite review....
125	Ted Thompson, JD, Chief Executive Officer Parkinson's Action Network	...single IRBs may also raise ethical, safety, and liability questions, including review quality and the possible loss of the safety net of redundant review. In further development of the policy, we urge NIH to consider and address these potential concerns through a lens that always considers first what is in the best interests of the patients and participants....
130	Janice Q At a small religious institution	As a small religious institution we have certain values and norms that a central IRB may not be aware of and even if they are aware of them would be unable to appropriately address without being part of that culture.... if there is only a single IRB review it seems it would bypass our controls for COI or necessitate more work on the part of the institution since we currently have a COI review process integrated into the IRB electronic system. That system is currently set up to put a hold on IRB studies where the research conflict of interest has not been cleared....
132	Vanderbilt University Medical Center	...a "single IRB of record" can be accomplished in several ways... Significant challenges limit each of these models. First, a single IRB of record only streamlines one portion of the approval process: the IRB regulatory review. Human subjects research also requires other institutional reviews that fall under the umbrella of Human Research Protection Programs (HRPP) such as PI training and eligibility and ancillary committee reviews. These ancillary reviews cannot be centralized; thus, the local HRPP must be involved in every study approval, regardless of the use of a single IRB of record.... Fifth, single IRB models can be difficult for local investigators to navigate and may result in conflation of investigator responsibilities and obligations. ...investigators often think they have ceded their research responsibilities to the investigator at the IRB of record institution....

Fig 18a. Selected ethical concerns raised before the NIH single-IRB mandate (2017).

Selected ethical concerns raised before NIH single-IRB mandate (2017)		
#	Commenter	Excerpt
133	Kelley A. O'Donoghue, MPH, CIP, Director, Office for Human Subject Protection, University of Rochester	The draft policy indicates that **"The single IRB will be accountable for compliance with regulatory requirements for IRBs specified under the HHS regulations at 45 CFR part 46, such as providing initial and continuing review of the research. All participating sites will be responsible for meeting other regulatory obligations, such as obtaining informed consent, overseeing the implementation of approved protocols, and, reporting unanticipated problems and adverse events to the single IRB of record."** What is stated here is not consistent with the Common Rule and the assurance regulations (section 103), which holds the IRB of record responsible for the site conduct.... ...IRB review is just one step in the local review and approval process.... While the University's IRBs have a pivotal role, overall protections are provided to subjects through coordinated interaction with other regulatory review entities within the institution.... IRBs receive information and feedback from other components of the HRPP.... There is the potential for negative impact on established HRPPs, resulting in reduced ability for coordinated oversight and implementation of systems and safeguards to protect human subjects at the local level.... ...The NIH should consider, in the process of reviewing this draft policy, specifically seeking out opinions from the potential research subjects who would be affected by the policy. Research subjects may (or may not) value other characteristics of human
141	Linda Halstead Submitted personally by an IRB Director at a mid-size healthcare academic institution	The founding purpose of the Institutional Review Board was built on the laudable concept of local, i.e., institutional responsibility. Indeed it is the local institution which relies on the good will of its community, and in the case of our institution its community is both geographic and cultural, being a lead research entity within the international religious organization which supports it. As is true for all institution-based IRBs, our IRB is the logical force for incorporating local culture and customs wherever our investigators conduct their research. Other examples of institutional concerns that are tied to the IRB process include conflict of interest management, HIPAA compliance, and investigator education. How a central IRB can either incorporate those responsibilities or divest itself from them is manifestly unclear.... our IRB is at the heart of an entire administrative system of checks and balances.
145	IRB Leadership and Enhancement Committee, on behalf of Virginia Commonwealth University Human Research Protection Program	The draft policy states, **"Importantly, there is no evidence that multiple IRB reviews enhance protections for human subjects. In fact, the use of single IRBs may lead to enhanced protections for research participants..."** ....Reliance on a central IRB seems to run counter to the intent of the regulatory requirements for IRB approval of EFIC [Exception from Informed Consent] research. ...assuring that adequate plans are in place to conduct community consultation and disclosure....
157	Alan Richmond, Community—Campus Partnerships for Health, Raleigh, NC Paige Castro, Community—Campus Partnerships for Health, Seattle, WA, et al	...the draft policy will undermine the ability of communities involved in and/or impacted by the research being reviewed to not only contribute to its ethical analysis, but to even be aware that a study has been proposed.... ...institutional IRBs do not adequately assess the community and cultural ethical implications of the research they review.... ...a growing number of community groups and Tribes have developed their own research ethics review processes that operate independently or in conjunction with institution-based IRBs.... ...Further, we found that community-based processes for research ethics review routinely consider research ethics and integrity issues that institutional IRBs normally do not, such as culturally appropriate recruitment strategies, opportunities for community capacity building, shared power and resources among study partners, and plans to share findings with involved communities....
164	Indian Health Service National Institutional Review Board	Regarding the statement, **"contextual issues relevant to most studies can be addressed through mechanisms other than local IRB, such as the involvement of ad hoc members or consultants with the necessary specialized knowledge or experience or by submission of information by the individual site(s)"**, it is unclear what is meant by "contextual issues" but this should not include the important considerations of social, cultural, and spiritual considerations in communicating risk and benefits of participation in research studies among and with Tribal members. Moreover, the "involvement of ad hoc members or consultants" could be interpreted to require that only 1 member of any Tribe, regardless of his or her affiliation with any one of the 566 federally-recognized Tribes or level of understanding of the cultural milieu of the population(s) under study, would be needed to satisfy this requirement....
167	Secretary's Advisory Committee on Human Research Protection (SACHRP)	While the use of single IRBs may be effective and efficient in some circumstances, SACHRP believes that it is premature at this time to mandate single IRB use in NIH funded domestic multi-center trials. Requiring a single IRB to review a multi-site research protocol may well, as described below, result in new procedures and policies being created by the relying institutions (those institutions relying on another institution to conduct the IRB review) and the reviewing institution (the institution responsible for serving as the single IRB of record) that will undermine the goals of this policy change and create a host of new challenges for research institutions.... The NIH draft policy focuses on "efficiency" as a key reason for requiring and justifying mandatory single IRB review. However, substantial experience suggests that the IRB review contributes only modest if any to the delays between project inception and subject recruitment.... SACHRP strongly maintains at this time that a uniform mandate of single IRB review for all domestic multi-site studies is premature.
ABBREVIATIONS: CFR = code of Federal regulations, COI = conflict of interest, EFIC = Exception from Informed Consent Research, HHS = US Department of Health and Human Services, HIPAA = Health Insurance Portability and Accountability Act of 1996, HRPP = Human Research Protection Program, IRB = institutional review board, OHRP = Office of Human Research Protections, SACHRP = Secretary's Advisory Committee on Human Research Protections, NIH = National Institutes of Health, PI = principal investigator, sIRB = single IRB.		

Fig 18b. Selected ethical concerns raised before the NIH single-IRB mandate (2017).

Reduced oversight contradicts the original impetus for research governance—loss of faith in medical altruism:

> …the altruistic nature of medical care was woefully insufficient protection for patients even after such horrific revelations as the Nuremberg trials, the Tuskegee syphilis study, Dr. Beecher's exposé [312], and other such reports. These revelations engendered such a distrust of altruism in medicine, that federal legislation…. codified protection of human subjects requiring a structure and process for institutional review boards to approve all human subject research. Moreover, the enforcement is housed not in DHSS, NIH, or other institutions of medicine, but in the Office of Civil Rights [313].

It is unclear whether IRB review provides ethically sufficient protection for patients unaware of medical research when regulations waive written consent. Waivers are made for practicality—it is difficult to obtain consent and enroll large numbers of participants in research studies, so it is easier to streamline the process. However, because non-researchers often lack detailed understanding of what research is, how research data are used, or representation on IRBs, it begs the question of whether this streamlining represents the best interests of the community being studied or just makes it easier for researchers to engage in research.

5.5 Black is White

Black Americans are especially aware of inconsistent 'racial' categories, for example when traveling abroad and under immigrant bosses at work and in training, **Fig 19**.

Bay Staters Meet in Texas

Official United States AAF Photo by AAF Training Command

Boston Men Soon to Graduate From Bombardier School

Second Lieut. Cyril Burke, left, of Roxbury and Air Corpsman, Flight Officer Daniel Keel, Boston, exchange greetings after returning from a practice mission over the vast Texas bombing ranges, where both are learning the art of "Axis-blasters." They are members of a large Negro class of "Hell From Heaven Men" who will soon be graduated from the ranks of fledgling bombardiers at Midland Army Air Field, the AAF Central Flying Training Command's key bombardier base at Midland, Texas. Their class will mark the end of training for cadets at the headquarters field of the nation's bombardier training program, which will be converted into the Army Air Forces Instructors School (Bombardier) for returned combat bombardiers.

First Lt. Vernon W. Burke of Boston, Mass., stands in front of his P-51 Mustang fighter, wearing the "Horseshoe" of the 18th Fighter - Bomber Wing's "Mustang Century Flight." The 24-year-old pilot has just completed his 100th combat mission against the Communists in Korea. Burke graduated from pilot training in Oct. 1948 and flew jet fighters before coming to Korea last January, when he joined the 18th Wing, the only Mustang unit in Korea. Before entering the Air Force, Burke graduated from the Boston Trade High School. He is the son of Mr. and Mrs. Cyril O. Burke Sr., Boston.

Kenneth M. Burke, above, Roxbury, was among the graduates of Tufts College in June. He received a degree in Engineering. He also was commissioned Ensign in the Navy. Kenneth has been a member of the Civic Symphony Orchestra of Boston for the past year. (The only colored member.)

Fig 19. Irresistible inconsistency meets immovable 'racial' beliefs. Consider three brothers, family of one of the authors (cob3). During segregation, newspapers reported "Negro" and "colored". After the Civil Rights Movement [314], self-identification embraced "Black" and "African American". Two senior academic physicians from Canada and South Africa insisted, respectively, on "White" and "NOT black".

ACKNOWLEDGMENTS

In memory of Rear Admiral W. Norman Johnson and many others who endured kidney failure after being prescribed nephrotoxic drugs that might have been avoided with early warning and caution, and of the Rev. Dr. Canon Cyril C. Burke, Sr., who taught ethics and whose final medical care was complicated by 'race'.

The authors gratefully acknowledge Edward Feller, MD, FACP, FACG, Ruth Levy Guyer, PhD, James M. Gilchrist, Professor Emeritus of Neurology at Southern Illinois University School of Medicine, and anonymous colleagues for critical review of a draft of

this article, and Joseph J. Fins, MD, MACP, FRCP, and John C. Kotelly, PhD, US Air Force mathematician (ret.), for their insights.

Competing Interests

The authors have declared that no competing interests exist.

Funding

The authors received no specific funding for this work.

ABBREVIATIONS

AKI = acute kidney injury, APOL1 = apolipoprotein L1, BS = bad science, CKD = chronic kidney disease, COI = conflict of interest, COVID = coronavirus disease, eGFR = estimated GFR, EU = European Union, FSGS = focal segmental glomerulosclerosis, FDA = Food and Drug Administration, GFR = glomerular filtration rate, GWAS = genome-wide association study, HR = high risk, IRB = institutional review board, LR = low risk, KF = kidney failure, MDRD = Modification of Diet in Renal Disease, NASEM = National Academies of Sciences Engineering and Medicine, OR = odds ratio, PCT = pragmatic clinical trials, RR = relative risk, RV = risk variant, SDOH = social determinants of health, sIRB = single IRB, UK = United Kingdom, US = United States, VA = Veterans Administration.

KEYWORDS

Apolipoprotein L1; APOL1; Bad science; Chronic kidney disease; CKD; Ethical Review; Ethics Committee; Institutional Review Board; IRB; Justice; N264K; Race; Racial disparity; Racism; Social determinants of health; SDOH; Veteran; Veterans.

REFERENCES

1. Burke CO, Burke LM, Tanzer JR. Pre-chronic kidney disease: Serial creatinine tracks glomerular filtration rate decline above 60 mL/min. medRxiv preprint doi: 10.1101/2024.09.17.24313678

2. Hunt LM, Truesdell ND, Kreiner MJ. Genes, race, and culture in clinical care: racial profiling in the management of chronic illness. Med Anthropol Q. 2013 Jun;27(2):253-71. doi: 10.1111/maq.12026. Epub 2013 Jun 26. PMID: 23804331; PMCID: PMC4362784.

3. European Commission: Directorate-General for Justice and Consumers, Farkas L. The meaning of racial or ethnic origin in EU law : between stereotypes and identities. Publications Office; 2017. Available from: doi/10.2838/83148

4. Zaslavsky AM, Ayanian JZ, Zaborski LB. The validity of race and ethnicity in enrollment data for Medicare beneficiaries. Health Serv Res. 2012 Jun;47(3 Pt 2):1300-21. doi: 10.1111/j.1475-6773.2012.01411.x. Epub 2012 Apr 19. PMID: 22515953; PMCID: PMC3349013.

5. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E. The validity of race and Hispanic origin reporting on death certificates in the United States. Vital Health Stat 2. 2008 Oct;(148):1-23. PMID: 19024798.

6. Clarke LC, Rull RP, Ayanian JZ, Boer R, Deapen D, West DW, et al. Validity of Race, Ethnicity, and National Origin in Population-based Cancer Registries and Rapid Case Ascertainment Enhanced With a Spanish Surname List. Med Care. 2016 Jan;54(1):e1-8. doi: 10.1097/MLR.0b013e3182a30350. PMID: 23938598; PMCID: PMC4449309.

7. Martino SC, Elliott MN, Haas A, Peltz A, Saliba D, Hassan S, et al. Assessing the accuracy of race-and-ethnicity data in the Outcome and Assessment Information Set. J Am Geriatr Soc. 2024 Aug;72(8):2508-2515. doi: 10.1111/jgs.18889. Epub 2024 Mar 21. PMID: 38511724.

8. Jarrín OF, Nyandege AN, Grafova IB, Dong X, Lin H. Validity of Race and Ethnicity Codes in Medicare Administrative Data Compared With Gold-standard Self-reported Race Collected During Routine Home Health Care Visits. Med Care. 2020 Jan;58(1):e1-e8. doi: 10.1097/MLR.0000000000001216. PMID: 31688554; PMCID: PMC6904433.

9. Huang AW, Meyers DJ. Assessing the validity of race and ethnicity coding in administrative Medicare data for reporting outcomes among Medicare advantage beneficiaries from 2015 to 2017. Health Serv Res. 2023 Oct;58(5):1045-1055. doi: 10.1111/1475-6773.14197. Epub 2023 Jun 25. PMID: 37356821; PMCID: PMC10480088.

10. Sojka PC, Maron MM, Dunsiger SI, Belgrave C, Hunt JI, Brannan EH, Wolff JC. Evaluation of Reliability Between Race and Ethnicity Data Obtained from Self-report Versus Electronic Health Record. J Racial Ethn Health Disparities. 2025 Aug;12(4):2200-2203. doi: 10.1007/s40615-024-02041-w. Epub 2024 Jun 5. PMID: 38839729; PMCID: PMC11634015.

11. Lu C, Ahmed R, Lamri A, Anand SS. Use of race, ethnicity, and ancestry data in health research. PLOS Glob Public Health. 2022 Sep 15;2(9):e0001060. doi: 10.1371/journal.pgph.0001060. PMID: 36962630; PMCID: PMC10022242.

12. National Academies of Sciences, Engineering, and Medicine. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field. Washington, DC: National Academies Press (US), 2023 Mar 14. PMID: 36989389. doi: 10.17226/26902.

13. Schneider EC, Shah A, Doty MM, Tikkanen R, Fields K, Williams II RD. Mirror, Mirror 2021—Reflecting Poorly: Health Care in the U.S. Compared to Other High-Income Countries. Commonwealth Fund, Aug. 2021. doi: 10.26099/01dv-h208.

14. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13. PMID: 32061315; PMCID: PMC7049905.

15. Ogungbe O, Turkson-Ocran RA, Tomiwa T, Adeleye K, Rayani A, Hinneh T, Baptiste D, Hladek MD, Crews DC, Commodore-Mensah Y. Nativity, Racial/Ethnic, and Length of US Residence Differences in Chronic Kidney Disease: National Health and Nutrition Examination Survey 2011-March 2020. Res Sq [Preprint]. 2025 Jan 8:rs.3.rs-5760383. doi: 10.21203/rs.3.rs-5760383/v1. PMID: 39866871; PMCID: PMC11760252.

16. Galvani AP, Parpia AS, Pandey A, Sah P, Colón K, Friedman G, et al. Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2200536119. doi: 10.1073/pnas.2200536119. Epub 2022 Jun 13. PMID: 35696578; PMCID: PMC9231482.

17. Institute of Medicine (US) Committee to Study Decision Making; Hanna KE, editor. Biomedical Politics. Washington (DC): National Academies Press (US); 1991. Origins of the Medicare Kidney Disease Entitlement: The Social Security Amendments of 1972. Available from: https://www.ncbi.nlm.nih.gov/books/NBK234191/

18. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020. [cited 2022 November 25]. Available from: https://usrds-adr.niddk.nih.gov/2022

19. Churchwell K, Elkind MSV, Benjamin RM, Carson AP, Chang EK, Lawrence W, et al; American Heart Association. Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory From the American Heart Association. Circulation. 2020 Dec 15;142(24):e454-e468. doi: 10.1161/CIR.0000000000000936. Epub 2020 Nov 10. PMID: 33170755.

20. Bailey ZD, Feldman JM, Bassett MT. How Structural Racism Works - Racist Policies as a Root Cause of U.S. Racial Health Inequities. N Engl J Med. 2021 Feb 25;384(8):768-773. doi: 10.1056/NEJMms2025396. Epub 2020 Dec 16. PMID: 33326717; PMCID: PMC11393777.

21. Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am J Kidney Dis. 2016 Dec;68(6):862-872. doi: 10.1053/j.ajkd.2016.05.030. Epub 2016 Aug 28. PMID: 27578184; PMCID: PMC5123906.

22. National Safety Council estimates based on data from National Center for Health Statistics – Mortality Data for 2019, population and life expectancy data from the U.S. Census Bureau, deaths classified on the basis of the 10th Revision of the World Health Organization's "The International Classification of Diseases" (ICD) [cited 2021 December 31]. Available from: https://injuryfacts.nsc.org/all-injuries/preventable-death-overview/odds-of-dying/

23. Norris KC, Williams SF, Rhee CM, Nicholas SB, Kovesdy CP, Kalantar-Zadeh K, et al. Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society. Semin Dial. 2017 May;30(3):213-223. doi: 10.1111/sdi.12589. Epub 2017 Mar 9. PMID: 28281281; PMCID: PMC5418094.

24. LaVeist TA, Pérez-Stable EJ, Richard P, Anderson A, Isaac LA, Santiago R, et al. The Economic Burden of Racial, Ethnic, and Educational Health Inequities in the US. JAMA. 2023 May 16;329(19):1682-1692. doi: 10.1001/jama.2023.5965. Erratum in: JAMA. 2023 Jun 6;329(21):1886. PMID: 37191700.

25. Benjamins MR, Lorenz P, Saiyed NS, Silva A, Mattix-Kramer HJ, Pys P, et al. Black-White Inequities in Kidney Disease Mortality Across the 30 Most Populous US Cities. J Gen Intern Med. 2022 May;37(6):1351-1358. doi: 10.1007/s11606-022-07444-1. Epub 2022 Mar 9. PMID: 35266122; PMCID: PMC9086025.

26. Silva A, Saiyed NS, Canty E, Benjamins MR. Pre-pandemic trends and Black:White inequities in life expectancy across the 30 most populous U.S. cities: a population-based study. BMC Public Health. 2023 Nov 22;23(1):2310. doi: 10.1186/s12889-023-17214-1. PMID: 37993811; PMCID: PMC10664538.

27. Boston Public Health Commission. Closing the Gap: An Examination of Life Expectancy Among Black Residents in Boston. Health of Boston Data Brief. 2026 February 27 [cited: 2026 March 15]. Available from: https://www.boston.gov/sites/default/files/file/2026/02/HealthOfBostonDataBrief_ClosingTheGap_2026_1.pdf

28. Albano L, Nickerson S. Life expectancy gap between Black residents and other Bostonians has doubled over the past decade. The Boston Globe. 2026 March 11 [cited: 2026 March 15]. Available from: https://www.bostonglobe.com/2026/03/12/metro/takeaways-boston-live-expectancy/

29. Ashkar ZM, Gottumukkala R. Using Machine Learning to Identify Geographic and Socioeconomic Disparities in Dialysis Facility Outcomes Across the United States. Ochsner J. 2025 Fall;25(3):170-180. doi: 10.31486/toj.25.0040. PMID: 40995155; PMCID: PMC12456289.

30. Racial Inclusivity of U.S. News Honor Roll Hospitals. In 2021 Winning Hospitals: Racial Inclusivity. The Lown Institute [online]. 2022 March 17 [cited 2022 March 27]. Available from: https://lownhospitalsindex.org/

31. Lee DC, Liang H, Shi L. The convergence of racial and income disparities in health insurance coverage in the United States. Int J Equity Health. 2021 Apr 7;20(1):96. doi: 10.1186/s12939-021-01436-z. PMID: 33827600; PMCID: PMC8025443.

32. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Smedley BD, Stith AY, Nelson AR, editors. Washington (DC): National Academies Press (US); 2003. PMID: 25032386.

33. McFarling UL. 20 years ago, a landmark report spotlighted systemic racism in medicine. Why has so little changed? Stat News. 2022 February 23 [cited 2023 June 6]. Available from: https://www.statnews.com/2022/02/23/landmark-report-systemic-racism-medicine-so-little-has-changed/

34. Vyas DA, Eisenstein LG, Jones DS. Hidden in Plain Sight - Reconsidering the Use of Race Correction in Clinical Algorithms. N Engl J Med. 2020 Aug 27;383(9):874-882. doi: 10.1056/NEJMms2004740. Epub 2020 Jun 17. PMID: 32853499.

35. Singh S. Racial biases in healthcare: Examining the contributions of Point of Care tools and unintended practitioner bias to patient treatment and diagnosis. Health (London). 2021 Dec 7:13634593211061215. doi: 10.1177/13634593211061215. Epub ahead of print. PMID: 34875900.

36. Cerdeña JP, Asabor EN, Plaisime MV, Hardeman RR. Race-based medicine in the point-of-care clinical resource UpToDate: A systematic content analysis. EClinicalMedicine. 2022 Jul 29;52:101581. doi: 10.1016/j.eclinm.2022.101581. PMID: 35923427; PMCID: PMC9340501.

37. Hunt LM, Kreiner MJ. Pharmacogenetics in primary care: the promise of personalized medicine and the reality of racial profiling. Cult Med Psychiatry. 2013 Mar;37(1):226-35. doi: 10.1007/s11013-012-9303-x. PMID: 23264029; PMCID: PMC3593998.

38. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005 Feb;113(2):192-200. doi: 10.1289/ehp.7337. PMID: 15687057; PMCID: PMC1277864.

39. Mehta RL, Burdmann EA, Cerdá J, Feehally J, Finkelstein F, García-García G, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. Lancet. 2016 May 14;387(10032):2017-25. doi: 10.1016/S0140-6736(16)30240-9. Epub 2016 Apr 13. Erratum in: Lancet. 2016 May 14;387(10032):1998. PMID: 27086173.

40. Hsu RK, Hsu CY. The Role of Acute Kidney Injury in Chronic Kidney Disease. Semin Nephrol. 2016 Jul;36(4):283-92. doi: 10.1016/j.semnephrol.2016.05.005. PMID: 27475659; PMCID: PMC4979984.

41. Wang HW, Jiang MY. Higher volume of water intake is associated with lower risk of albuminuria and chronic kidney disease. Medicine (Baltimore). 2021 May 21;100(20):e26009. doi: 10.1097/MD.0000000000026009. PMID: 34011099; PMCID: PMC8137104.

42. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e136-e139. Erratum in: Hypertension. 2018 Sep;72(3):e33. PMID: 29133354.

43. Holt HK, Gildengorin G, Karliner L, Fontil V, Pramanik R, Potter MB. Differences in Hypertension Medication Prescribing for Black Americans and Their Association with Hypertension Outcomes. J Am Board Fam Med. 2022 Jan-Feb;35(1):26-34. doi: 10.3122/jabfm.2022.01.210276. PMID: 35039409.

44. Fitzpatrick JK, Yang J, Ambrosy AP, Cabrera C, Stefansson BV, Greasley PJ, et al. Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study. BMJ Open. 2022 Jan 31;12(1):e048755. doi: 10.1136/bmjopen-2021-048755. PMID: 35105612; PMCID: PMC8808372.

45. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506. PMID: 26551272; PMCID: PMC4689591.

46. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, et al; SPRINT Research Group. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial

(SPRINT). Am J Kidney Dis. 2018 Mar;71(3):352-361. doi: 10.1053/j.ajkd.2017.08.021. Epub 2017 Nov 20. PMID: 29162340; PMCID: PMC5828778.

47. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021 Dec 30;385(27):2507-2519. doi: 10.1056/NEJMoa2110730. Epub 2021 Nov 5. PMID: 34739197.

48. Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E, et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 2011 Mar;79(5):555-62. doi: 10.1038/ki.2010.462. Epub 2010 Nov 24. PMID: 21107446; PMCID: PMC4220293.

49. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al, and Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009 Jun;53(6):982-92. doi: 10.1053/j.ajkd.2008.12.034. Epub 2009 Apr 1. PMID: 19339088.

50. Lee CS, Cha RH, Lim YH, Kim H, Song KH, Gu N, et al. Ethnic coefficients for glomerular filtration rate estimation by the Modification of Diet in Renal Disease study equations in the Korean population. J Korean Med Sci. 2010 Nov;25(11):1616-25. doi: 10.3346/jkms.2010.25.11.1616. Epub 2010 Oct 26. PMID: 21060751; PMCID: PMC2966999.

51. Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin P, Susantitaphong P, et al. The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant. 2011 Sep;26(9):2780-5. doi: 10.1093/ndt/gfq815. Epub 2011 Feb 28. PMID: 21357214.

52. Liu X, Gan X, Chen J, Lv L, Li M, Lou T. A new modified CKD-EPI equation for Chinese patients with type 2 diabetes. PLoS One. 2014 Oct 14;9(10):e109743. doi: 10.1371/journal.pone.0109743. PMID: 25313918; PMCID: PMC4196932.

53. Martin T. The color of kidneys. Am J Kidney Dis. 2011 Nov;58(5):xxvii-xxviii. doi: 10.1053/j.ajkd.2011.08.018. PMID: 22014639.

54. Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011 Jul;58(1):56-63. doi: 10.1053/j.ajkd.2011.02.393. Epub 2011 May 20. PMID: 21601325.

55. Umeukeje EM, Koonce TY, Kusnoor SV, Ulasi II, Kostelanetz S, Williams AM, et al. Systematic review of international studies evaluating MDRD and CKD-EPI estimated glomerular filtration rate (eGFR) equations in Black adults. PLoS One. 2022 Oct 18;17(10):e0276252. doi: 10.1371/journal.pone.0276252. PMID: 36256652; PMCID: PMC9578594.

56. Eneanya ND, Boulware LE, Tsai J, Bruce MA, Ford CL, Harris C, et al. Health inequities and the inappropriate use of race in nephrology. Nat Rev Nephrol. 2022 Feb;18(2):84-94. doi: 10.1038/s41581-021-00501-8. Epub 2021 Nov 8. PMID: 34750551; PMCID: PMC8574929.

57. Hsu CY. Eliminating the race coefficient in kidney function estimating equations: The center did hold. Trans Am Clin Climatol Assoc. 2023;133:247-261. PMID: 37701614; PMCID: PMC10493757.

58. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al; Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23. PMID: 34554658.

59. Björk J, Grubb A, Sterner G, Nyman U. A new tool for predicting the probability of chronic kidney disease from a specific value of estimated GFR. Scand J Clin Lab Invest. 2010 Sep;70(5):327-33. doi: 10.3109/00365513.2010.488699. PMID: 20545460.

60. Kasozi RN, Meeusen JW, Lieske JC. Estimating glomerular filtration rate with new equations: can one size ever fit all? Crit Rev Clin Lab Sci. 2023 Nov;60(7):549-559. doi: 10.1080/10408363.2023.2214812. Epub 2023 Jun 1. PMID: 37259709; PMCID: PMC10592396.

61. Tsai JW, Cerdeña JP, Goedel WC, Asch WS, Grubbs V, Mendu ML, Kaufman JS. Evaluating the Impact and Rationale of Race-Specific Estimations of Kidney Function: Estimations from U.S. NHANES, 2015-2018. EClinicalMedicine. 2021 Nov 19;42:101197. doi: 10.1016/j.eclinm.2021.101197. PMID: 34849475; PMCID: PMC8608882.

62. Khazanchi R, Fleishman A, Eneanya ND, Michelson KA, Diao JA, Morse M, Pavlakis M. Wait Time Modifications for Black Transplant Candidates Affected by Race-Based Kidney Function Estimation. JAMA Intern Med. 2026 Mar 9:e260001. doi: 10.1001/jamainternmed.2026.0001. Epub ahead of print. PMID: 41801177; PMCID: PMC12973219.

63. Kuhn TS. The structure of scientific revolutions, 4th ed. Chicago, IL: The University of Chicago Press; 2012.

64. McFarling UL. Troubling podcast puts JAMA, the 'voice of medicine,' under fire for its mishandling of race. Stat News. 2021 April 6 [cited 2022 August 31]. Available from: https://www.statnews.com/2021/04/06/podcast-puts-jama-under-fire-for-mishandling-of-race/

65. Chander, A. (2016). The racist algorithm. Mich. L. Rev., 115, 1023. Available from: https://repository.law.umich.edu/cgi/viewcontent.cgi?article=1657&context=mlr

66. Williams P. Retaining Race in Chronic Kidney Disease Diagnosis and Treatment. Cureus. 2023 Sep 11;15(9):e45054. doi: 10.7759/cureus.45054. PMID: 37701164; PMCID: PMC10495104.

67. Watson-Daniels J. Algorithmic Fairness and Color-blind Racism: Navigating the Intersection. arXiv preprint, 2024. arXiv:2402.07778. Available from: https://arxiv.org/pdf/2402.07778

68. Desai, J., Watson, D., Wang, V., Taddeo, M., Floridi, L. (2022). The epistemological foundations of data science: a critical review. Synthese, 200(6), 469. Available from: https://link.springer.com/article/10.1007/s11229-022-03933-2

69. Lincoln A. Second Inaugural Address, 1865. Available from: https://www.gilderlehrman.org/history-resources/spotlight-primary-source/president-lincolns-second-inaugural-address-1865

70. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial differences in risk of end-stage renal disease and death. Am J Med. 2009 Jul;122(7):672-8. doi: 10.1016/j.amjmed.2008.11.021. PMID: 19559170; PMCID: PMC2749005.

71. Hung AM, Shah SC, Bick AG, Yu Z, Chen HC, Hunt CM, et al; VA Million Veteran Program COVID-19 Science Initiative. APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Intern Med. 2022 Apr 1;182(4):386-395. doi: 10.1001/jamainternmed.2021.8538. PMID: 35089317; PMCID: PMC8980930.

72. Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney Outcomes in Long COVID. J Am Soc Nephrol. 2021 Nov;32(11):2851-2862. doi: 10.1681/ASN.2021060734. Epub 2021 Sep 1. PMID: 34470828; PMCID: PMC8806085.

73. Verbeek JH, Whaley P, Morgan RL, Taylor KW, Rooney AA, Schwingshackl L, et al; GRADE Working Group. An approach to quantifying the potential importance of residual confounding in systematic reviews of observational studies: A GRADE concept paper. Environ Int. 2021 Dec;157:106868. doi: 10.1016/j.envint.2021.106868. Epub 2021 Sep 13. PMID: 34530289.

74. de Almeida DC, Franco MDCP, Dos Santos DRP, Santos MC, Maltoni IS, Mascotte F, et al. Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. PLoS One. 2021 May 25;16(5):e0251048. doi: 10.1371/journal.pone.0251048. PMID: 34033655; PMCID: PMC8148326.

75. Hung AM, Assimon VA, Chen HC, Yu Z, Vlasschaert C, Triozzi JL, et al; Million Veteran Program. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease. J Am Soc Nephrol. 2023 Nov 1;34(11):1889-1899. doi: 10.1681/ASN.0000000000000219. Epub 2023 Oct 6. PMID: 37798822; PMCID: PMC10631602.

76. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016 Feb;70:214-23. doi: 10.1016/j.jclinepi.2015.09.016. Epub 2015 Oct 9. PMID: 26441289.

77. Boyd RW, Lindo EG, Weeks LD, McLemore MR. On Racism: A New Standard For Publishing On Racial Health Inequities. Health Affairs Blog, 2020 July 2 [cited 2024 January 24]. Available from: https://www.healthaffairs.org/content/forefront/racism-new-standard-publishing-racial-health-inequities

78. Gamble VN. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997 Nov;87(11):1773-8. doi: 10.2105/ajph.87.11.1773. PMID: 9366634; PMCID: PMC1381160.

79. Ibrahim Z, Brown C, Crow B, Roumimper H, Kureshi S. The Propagation of Race and Racial Differences as Biological in Preclinical Education. Med Sci Educ. 2022 Jan 10;32(1):209-219. doi: 10.1007/s40670-021-01457-x. PMID: 35186437; PMCID: PMC8814266.

80. Roberts DE. Reconciling Equal Protection Law in the Public and in the Family: The Role of Racial Politics. University of Pennsylvania Law School, Legal Scholarship Repository, Faculty Scholarship, Paper 1624. 2014 [cited 2022 July 5]. Available from: http://scholarship.law.upenn.edu/faculty_scholarship/1624

81. Mulinari S, Bredström A. "Black race", "Schwarze Hautfarbe", "Origine africaine", or "Etnia nera"? The absent presence of race in European pharmaceutical regulation. BioSocieties. 2022 Dec 14. doi: 10.1057/s41292-022-00291-7

82. Bentz M, Saperstein A, Fullerton SM, Shim JK, Lee SS. Conflating race and ancestry: Tracing decision points about population descriptors over the precision medicine research life course. HGG Adv. 2024 Jan 11;5(1):100243. doi: 10.1016/j.xhgg.2023.100243. Epub 2023 Sep 27. PMID: 37771152; PMCID: PMC10585473.

83. Liu P, Ross JS, Ioannidis JP, Dhruva SS, Vasiliou V, Wallach JD. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. Clin Trials. 2020 Apr;17(2):231-234. doi: 10.1177/1740774519887148. Epub 2019 Nov 10. PMID: 31709809.

84. Gates HL Jr, Curran AS. Who's Black and why?: a hidden chapter from the eighteenth-century invention of race. The Belknap Press of Harvard University Press, 2022.

85. Jacoby J. Science says race isn't real. How long will the US Census keep pretending otherwise? The Boston Globe. 2024 April 7 [cited 2024 April 7]. Available from: https://www.bostonglobe.com/2024/04/07/opinion/census-race-mena-hispanic-latino/

86. Trent S. Race isn't real, science says. Advocates want the census to reflect that. The Washington Post. 2023 October 16 [cited 2023 October 16]. Available from: https://www.washingtonpost.com/dc-md-va/2023/10/16/census-race-eliminate-race-box/

87. Hodge JL. Invitation to a Dialogue: The Myth of 'Race.' The New York Times. 2013 July 16 [cited 2021 December 31]. Available from: http://www.nytimes.com/2013/07/17/opinion/invitation-to-a-dialogue-the-myth-of-race.html

88. Matshidze KP, Richter LM, Ellison GT, Levin JB, McIntyre JA. Caesarean section rates in South Africa: evidence of bias among different 'population groups'. Ethn Health. 1998 Feb-May;3(1-2):71-9. doi: 10.1080/13557858.1998.9961850. PMID: 9673465; PMCID: PMC1876943.

89. Shalikashvili JM, Shelton H, Clark W, Hawley RE, Johnnie E. Wilson JE, et al. Ready, Willing, And Unable To Serve, 75 Percent of Young Adults Cannot Join the Military: Early Education across America is Needed to Ensure National Security. Mission: Readiness, Military Leaders for Kids. 2009 [cited 2022 Jan 20]. Available from: http://cdn.missionreadiness.org/NATEE1109.pdf

90. The 2019 National Assessment of Educational Progress (NAEP). National Center for Education Statistics [cited 2021 Dec 31]. Available from: https://nces.ed.gov/nationsreportcard/

91. Gupta S. Military towns are the most racially integrated places in the U.S. Here's why. Science News. 2022 February 8 [cited 2022 February 18]. Available from: https://www.sciencenews.org/article/military-towns-integration-segregation-united-states

92. Bureau of Labor Statistics: Employment Situation of Veterans – 2019. USDL-20-0452, 2020 March 19 (corrected 2020 Apr 22) [cited 2021 Dec 31]. Available from: https://www.bls.gov/news.release/pdf/vet.pdf

93. Peterson RD, Krivo LJ. Race, Residence, and Violent Crime: A Structure of Inequality. Kansas Law Review, 2009, Vol. 57. Available from: https://kuscholarworks.ku.edu/bitstream/handle/1808/20100/7.0-Peterson_Final.pdf, doi:10.17161/1808.20100

94. Sampson RJ, Bean L. Cultural Mechanisms and Killing Fields: A Revised Theory of Community-Level Racial Inequality. The Many Colors of Crime: Inequalities of Race, Ethnicity and Crime in America, edited by Ruth Peterson, Lauren Krivo, and John Hagan. New York: New York University Press, 2006. Available from: http://scholar.harvard.edu/files/sampson/files/2006_cultmech_bean.pdf

95. Takkavatakarn K, Mohottige D, Charney AW, Horowitz C, Rundle AG, Chan L, Nadkarni GN. Interaction Between *Apolipoprotein L1* Genetic Risk and Neighborhood Socioeconomic Status for Kidney Outcomes in a United States Cohort. Kidney Int Rep. 2025 Feb 25;10(5):1476-1485. doi: 10.1016/j.ekir.2025.02.015. PMID: 40485706; PMCID: PMC12142791.

96. Grobman B, Turkson-Ocran RA, Zhang M, Juraschek SP. Socioeconomic Status and Chronic Kidney Disease Among Black and White Adults: An Analysis of 2017-2020 NHANES. Kidney Med. 2025 Jun 16;7(8):101045. doi: 10.1016/j.xkme.2025.101045. PMID: 40740719; PMCID: PMC12309949.

97. Sula Karreci E, Jacas S, Donovan O, Pintye D, Wiley N, Zsengeller ZK, et al. Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2. Kidney Int. 2024 Dec;106(6):1072-1085. doi: 10.1016/j.kint.2024.07.026. Epub 2024 Aug 23. PMID: 39181397; PMCID: PMC11585418.

98. Olabisi OA. Has APOL1 kidney disease treatment been hiding in plain sight? Kidney Int. 2024 Dec;106(6):1015-1017. doi: 10.1016/j.kint.2024.09.003. PMID: 39577983.

99. Agunbiade A, Dasgupta A, Ward MM. Racial/Ethnic Differences in Dialysis Discontinuation and Survival after Hospitalization for Serious Conditions among Patients on Maintenance Dialysis. J Am Soc Nephrol. 2020 Jan;31(1):149-160. doi: 10.1681/ASN.2019020122. Epub 2019 Dec 13. PMID: 31836625; PMCID: PMC6935007.

100. Norris KC, Kalantar-Zadeh K. Can Dialysis Withdrawal Explain Why White Patients Have Worse Survival than Black Patients? J Am Soc Nephrol. 2020 Jan;31(1):2-4. doi: 10.1681/ASN.2019111187. Epub 2019 Dec 13. PMID: 31841436; PMCID: PMC6934993.

101. Sacco RL. Stroke Disparities: From Observations to Actions: Inaugural Edward J. Kenton Lecture 2020. Stroke. 2020 Nov;51(11):3392-3405. doi: 10.1161/STROKEAHA.120.030428. Epub 2020 Oct 26. PMID: 33104468; PMCID: PMC7594170.

102. Cha H, Farina MP, Jackson HM, Ailshire JA, Walsemann KM. How Childhood State Education Quality Shapes the Risk of Cognitive Impairment in Mid-to-Later Life. Alzheimers Dement Behav Socioecon Aging. 2026 Mar;2(1):e70061. doi: 10.1002/bsa3.70061. Epub 2026 Jan 12. PMID: 41586441; PMCID: PMC12826673.

103. Venketasubramanian N, Rundek T, Gan RN. Editorial: Stroke in minority groups and populations. Front Stroke. 2023 Nov 28;2:1315298. doi: 10.3389/fstro.2023.1315298. PMID: 41541119; PMCID: PMC12802709.

104. Warren RC, Forrow L, Hodge DA Sr, Truog RD. Trustworthiness before Trust - Covid-19 Vaccine Trials and the Black Community. N Engl J Med. 2020 Nov 26;383(22):e121. doi: 10.1056/NEJMp2030033. Epub 2020 Oct 16. PMID: 33064382.

105. Saeed F, Ladwig S, Allen RJ, Eneanya ND, Tamura MK, Fiscella KA. Racial Disparities in Health Beliefs and Advance Care Planning Among Patients Receiving Maintenance Dialysis. J Pain Symptom Manage. 2023 Apr;65(4):318-325. doi: 10.1016/j.jpainsymman.2022.12.002. Epub 2022 Dec 12. PMID: 36521766; PMCID: PMC10103744.

106. Popular and Pervasive Stereotypes of African Americans. The National Museum of African American History & Culture, Smithsonian Institution, [cited 2026 February 22]. Available from: https://nmaahc.si.edu/explore/stories/popular-and-pervasive-stereotypes-african-americans

107. Wolfe L. Eight reasons why victim-blaming needs to stop: Writers, activists, and survivors speak out. Women's Media Center, website [cited 2026 February 22]. Available from: https://womensmediacenter.com/women-under-siege/eight-reasons-why-victim-blaming-needs-to-stop-writers-activists-and-surviv

108. Hall WJ, Chapman MV, Lee KM, Merino YM, Thomas TW, Payne BK, et al. Implicit Racial/Ethnic Bias Among Health Care Professionals and Its Influence on Health Care Outcomes: A Systematic Review. Am J Public Health. 2015 Dec;105(12):e60-76. doi: 10.2105/AJPH.2015.302903. Epub 2015 Oct 15. PMID: 26469668; PMCID: PMC4638275.

109. Bady A. Chimamanda Ngozi Adichie: "Race doesn't occur to me." Salon website. 2013 July 14 [cited 2023 September 17]. Available from: https://www.salon.com/2013/07/14/chimamanda_ngozi_adichie_race_doesnt_occur_to_me_partner/

110. Green L. Negative Racial Stereotypes and Their Effect on Attitudes Toward African-Americans. Jim Crow Museum [cited 2026 February 22]. Available from: https://jimcrowmuseum.ferris.edu/links/essays/vcu.htm

111. Bonovas S, Piovani D. Simpson's Paradox in Clinical Research: A Cautionary Tale. J Clin Med. 2023 Feb 18;12(4):1633. doi: 10.3390/jcm12041633. PMID: 36836181; PMCID: PMC9960320.

112. Peterson K, Anderson J, Boundy E, Ferguson L, McCleery E, Waldrip K. Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map. Am J Public Health. 2018 Mar;108(3):e1-e11. doi: 10.2105/AJPH.2017.304246. PMID: 29412713; PMCID: PMC5803811.

113. Tsai S, Nguyen H, Ebrahimi R, Barbosa MR, Ramanan B, Heitjan DF, et al. COVID-19 associated mortality and cardiovascular disease outcomes among US women veterans. Sci Rep. 2021 Apr 19;11(1):8497. doi: 10.1038/s41598-021-88111-z. PMID: 33875764; PMCID: PMC8055870.

114. Miller G. Cultural Adaptations and Physical Variation: Clines and Folk Taxonomy. Leeward Community College. [cited 2022 September 5]. Available from: https://laulima.hawaii.edu/access/content/user/millerg/anth_150/a150unit3/clinesfolktaxonomy.html

115. Oppenheimer GM. Paradigm lost: race, ethnicity, and the search for a new population taxonomy. Am J Public Health. 2001 Jul;91(7):1049-55. doi: 10.2105/ajph.91.7.1049. PMID: 11441730; PMCID: PMC1446716.

116. Hunt LM, Megyesi MS. The ambiguous meanings of the racial/ethnic categories routinely used in human genetics research. Soc Sci Med. 2008 Jan;66(2):349-61. doi: 10.1016/j.socscimed.2007.08.034. Epub 2007 Oct 23. PMID: 17959289; PMCID: PMC2213883.

117. Deyrup A, Graves JL Jr. Racial Biology and Medical Misconceptions. N Engl J Med. 2022 Feb 10;386(6):501-503. doi: 10.1056/NEJMp2116224. Epub 2022 Feb 5. PMID: 35119803.

118. Posel D. What's in a name? Racial categorisations under apartheid and their afterlife. TRANSFORMATION. 47 (2001); 50-74. ISSN 0258-7696. Available from: http://transformationjournal.org.za/wp-content/uploads/2017/03/tran047005.pdf

119. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):177-82. doi: 10.1073/pnas.0126614100. Epub 2002 Dec 30. PMID: 12509516; PMCID: PMC140919.

120. Travassos C, Williams DR. The concept and measurement of race and their relationship to public health: a review focused on Brazil and the United States. Cad Saude Publica. 2004 May-Jun;20(3):660-78. doi: 10.1590/s0102-311x2004000300003. Epub 2004 May 19. PMID: 15263977.

121. Pokorak JJ. Rape as a Badge of Slavery: The Legal History of, And Remedies for, Prosecutorial Race-of-Victim Charging Disparities. Nevada Law Journal. Vol 7:1. 2006 Fall. Available from: https://scholars.law.unlv.edu/cgi/viewcontent.cgi?article=1418&context=nlj

122. Nobles M. History counts: a comparative analysis of racial/color categorization in US and Brazilian censuses. Am J Public Health. 2000 Nov;90(11):1738-45. doi: 10.2105/ajph.90.11.1738. PMID: 11076243; PMCID: PMC1446411.

123. Braun L, Fausto-Sterling A, Fullwiley D, Hammonds EM, Nelson A, Quivers W, et al. Racial categories in medical practice: how useful are they? PLoS Med. 2007 Sep;4(9):e271. doi: 10.1371/journal.pmed.0040271. PMID: 17896853; PMCID: PMC1989738.

124. Cusick MM, Sholle ET, Davila MA, Kabariti J, Cole CL, Campion TR Jr. A Method to Improve Availability and Quality of Patient Race Data in an Electronic Health Record System. Appl Clin Inform. 2020 Oct;11(5):785-791. doi: 10.1055/s-0040-1718756. Epub 2020 Nov 25. PMID: 33241548; PMCID: PMC7688409.

125. Klinger EV, Carlini SV, Gonzalez I, Hubert SS, Linder JA, Rigotti NA, Kontos EZ, Park ER, Marinacci LX, Haas JS. Accuracy of race, ethnicity, and language preference in an electronic health record. J Gen Intern Med. 2015 Jun;30(6):719-23. doi: 10.1007/s11606-014-3102-8. Epub 2014 Dec 20. PMID: 25527336; PMCID: PMC4441665.

126. Race and Ethnicity: Definitions, Theories, and the Indian Context. Literary Latitude [website]. 2025 February 9 [cited 2026 March 27]. Available from: https://literarylatitude.com/2025/02/09/race-and-ethnicity-definitions-theories-and-the-indian-context/

127. Rahman M. The Causes, Contributors, and Consequences of Colorism Among Various Cultures. Wayne State University. 2020 December 14. Available from: https://digitalcommons.wayne.edu/cgi/viewcontent.cgi?article=1069&context=honorstheses

128. Davis FJ. Who is Black? One Nation's Definition. Frontline. 2014 [cited 2024 April 3]. Available from: https://www.pbs.org/wgbh/pages/frontline/shows/jefferson/mixed/onedrop.html

129. Tabachnikov O, Skorecki K, Kruzel-Davila E. APOL1 nephropathy - a population genetics success story. Curr Opin Nephrol Hypertens. 2024 Feb 29. doi: 10.1097/MNH.0000000000000977. Epub ahead of print. PMID: 38415700.

130. Fang H, Hui Q, Lynch J, Honerlaw J, Assimes TL, Huang J, et al; VA Million Veteran Program; Sun YV, Tang H. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. Am J Hum Genet. 2019 Oct 3;105(4):763-772. doi: 10.1016/j.ajhg.2019.08.012. Epub 2019 Sep 26. PMID: 31564439; PMCID: PMC6817526.

131. Lipsky AM, Greenland S. Causal Directed Acyclic Graphs. JAMA. 2022 Mar 15;327(11):1083-1084. doi: 10.1001/jama.2022.1816. PMID: 35226050.

132. Roberts DE. Debating the Cause of Health Disparities: Implications for Bioethics and Racial Equality. University of Pennsylvania Law School, Legal Scholarship Repository, Faculty Scholarship, Paper 573. 2012 [cited: 2022 July 5]. https://scholarship.law.upenn.edu/faculty_scholarship/573

133. Gupta N, Waas B, Austin D, De Mazière AM, Kujala P, Stockwell AD, et al. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression. Sci Rep. 2024 Feb 14;14(1):3765. doi: 10.1038/s41598-024-53298-4. PMID: 38355600; PMCID: PMC10866943.

134. Braun L, Grisson R. Race, Lung Function, and the Historical Context of Prediction Equations. JAMA Netw Open. 2023 Jun 1;6(6):e2316128. doi: 10.1001/jamanetworkopen.2023.16128. PMID: 37261833.

135. Moffett AT, Bowerman C, Stanojevic S, Eneanya ND, Halpern SD, Weissman GE. Global, Race-Neutral Reference Equations and Pulmonary Function Test Interpretation. JAMA Netw Open. 2023 Jun 1;6(6):e2316174. doi: 10.1001/jamanetworkopen.2023.16174. PMID: 37261830; PMCID: PMC10236239.

136. Sjoding MW, Ansari S, Valley TS. Origins of Racial and Ethnic Bias in Pulmonary Technologies. Annu Rev Med. 2023 Jan 27;74:401-412. doi: 10.1146/annurev-med-043021-024004. Epub 2022 Jul 28. PMID: 35901314; PMCID: PMC9883596.

137. Valbuena VSM, Seelye S, Sjoding MW, Valley TS, Dickson RP, Gay SE, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013-19: multicenter, retrospective cohort study. BMJ. 2022 Jul 6;378:e069775. doi: 10.1136/bmj-2021-069775. PMID: 35793817; PMCID: PMC9254870.

138. Wong AI, Charpignon M, Kim H, Josef C, de Hond AAH, Fojas JJ, et al. Analysis of Discrepancies Between Pulse Oximetry and Arterial Oxygen Saturation Measurements by Race and Ethnicity and Association With Organ Dysfunction and Mortality. JAMA Netw Open. 2021 Nov 1;4(11):e2131674. doi: 10.1001/jamanetworkopen.2021.31674. Erratum in: JAMA Netw Open. 2022 Feb 1;5(2):e221210. PMID: 34730820; PMCID: PMC9178439.

139. Lee D, Kett PM, Mohammed SA, Frogner BK, Sabin J. Inequitable care delivery toward COVID-19 positive people of color and people with disabilities. PLOS Glob Public Health. 2023 Apr 19;3(4):e0001499. doi: 10.1371/journal.pgph.0001499. PMID: 37074996; PMCID: PMC10115306.

140. Sun M, Oliwa T, Peek ME, Tung EL. Negative Patient Descriptors: Documenting Racial Bias In The Electronic Health Record. Health Aff (Millwood). 2022 Feb;41(2):203-211. doi: 10.1377/hlthaff.2021.01423. Epub 2022 Jan 19. PMID: 35044842; PMCID: PMC8973827.

141. Pun PH, Svetkey LP, McNally B, Dupre ME; CARES Surveillance Group. Facility-Level Factors and Racial Disparities in Cardiopulmonary Resuscitation within US Dialysis Clinics. Kidney360. 2022 Mar 11;3(6):1021-1030. doi: 10.34067/KID.0008092021. PMID: 35845342; PMCID: PMC9255868.

142. Siemens TA, Riella MC, Moraes TP, Riella CV. APOL1 risk variants and kidney disease: what we know so far. J Bras Nefrol. 2018 Oct-Dec;40(4):388-402. doi: 10.1590/2175-8239-JBN-2017-0033. Epub 2018 Jul 26. PMID: 30052698; PMCID: PMC6533999.

143. Chen TK, Coresh J, Daya N, Ballew SH, Tin A, Crews DC, et al. Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study. J Am Geriatr Soc. 2021 Jan;69(1):155-163. doi: 10.1111/jgs.16797. Epub 2020 Sep 7. PMID: 32894582; PMCID: PMC7855571.

144. Grams ME, Matsushita K, Sang Y, Estrella MM, Foster MC, Tin A, et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol. 2014 Aug;25(8):1834-41. doi: 10.1681/ASN.2013080867. Epub 2014 Apr 10. PMID: 24722442; PMCID: PMC4116065.

145. Grams ME, Rebholz CM, Chen Y, Rawlings AM, Estrella MM, Selvin E, et al. Race, ApoL1 Risk, and eGFR Decline in the General Population. J Am Soc Nephrol. 2016 Sep;27(9):2842-50. doi: 10.1681/ASN.2015070763. Epub 2016 Mar 10. PMID: 26966015; PMCID: PMC5004654.

146. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517. doi: 10.2215/CJN.05960616. Epub 2017 Feb 27. Erratum in: Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1889. doi: 10.2215/CJN.12071018. PMID: 28242845; PMCID: PMC5338705.

147. De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol. 2018 Mar;29(3):759-774. doi: 10.1681/ASN.2017090958. Epub 2018 Jan 10. PMID: 29321142; PMCID: PMC5827609.

148. Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza FC. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J. 2018 Apr;11(2):179-190. doi: 10.1093/ckj/sfx143. Epub 2018 Jan 9. PMID: 29644057; PMCID: PMC5888331.

149. Bonilla M, Efe O, Selvaskandan H, Lerma EV, Wiegley N. A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations. Kidney Med. 2024 Apr 17;6(6):100826. doi: 10.1016/j.xkme.2024.100826. PMID: 38765809; PMCID: PMC11099322.

150. Harita Y. Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis. Clin Exp Nephrol. 2018 Jun;22(3):491-500. doi: 10.1007/s10157-017-1449-y. Epub 2017 Jul 27. PMID: 28752288; PMCID: PMC5956018.

151. Kallash M, Wang Y, Smith A, Trachtman H, Gbadegesin R, Nester C, et al. Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clin J Am Soc Nephrol. 2023 Mar 1;18(3):344-355. doi: 10.2215/CJN.0000000000000069. Epub 2023 Feb 8. PMID: 36763813; PMCID: PMC10103277.

152. Iltis AS, Walsh HA, Baldwin K, McIntosh T, Mohan S, Sawinski D, Goodman MS, DuBois JM. Insights From Black Living Kidney Donors: An Interview Study on APOL1 Genetic Testing Experiences. Clin Transplant. 2026 Feb;40(2):e70482. doi: 10.1111/ctr.70482. PMID: 41691638; PMCID: PMC12906861.

153. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30. Erratum in: PLoS Med. 2022 Aug 25;19(8):e1004085. doi: 10.1371/journal.pmed.1004085. PMID: 16060722; PMCID: PMC1182327.

154. Kahn J. Race, pharmacogenomics, and marketing: putting BiDil in context. Am J Bioeth. 2006 Sep-Oct;6(5):W1-5. doi: 10.1080/15265160600755789. PMID: 16997802.

155. Gurgel do Amaral MS, Reijneveld SA, Geboers B, Navis GJ, Winter AF. Low Health Literacy is Associated with the Onset of CKD during the Life Course. J Am Soc Nephrol. 2021 Jun 1;32(6):1436-1443. doi: 10.1681/ASN.2020081155. Epub 2021 Mar 25. PMID: 33766810; PMCID: PMC8259635.

156. Taylor DM, Fraser S, Dudley C, Oniscu GC, Tomson C, Ravanan R, et al; ATTOM investigators. Health literacy and patient outcomes in chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2018 Sep 1;33(9):1545-1558. doi: 10.1093/ndt/gfx293. PMID: 29165627.

157. Rosenbaum MD, Eidmann KA, Kelley MC, Wheeler JM, Miller BA, Caminker EH, et al. Gary B. v. Snyder ("Detroit Literacy Lawsuit"), Class Action Complaint. United States District Court, Eastern District of Michigan, Southern Division, Civil Action No.: 16-CV-13292, filed 2016 Sep 13 [cited 2021 Dec 31]. Available from: http://www.detroit-accesstoliteracy.org/wp-content/uploads/2016/09/2016-09-13-Complaint.pdf

158. Lyon R. Testimonies to Congress: 1997-2002 [cited 2024 January 13]. Available from: https://eric.ed.gov/?q=%22%22&ft=on&ff1=pubSpeeches%2FMeeting+Papers&ff2=lawElementary+and+Secondary+Education+Act+Title+I&id=ED475205

159. Lyon R. Part 3 1996 Testimony Assembly EdCommittee on Reading/Language Arts/Reid Lyon, NICHD 1991-2005, SES. 1996 [cited 2024 January 13]. Available from: https://www.youtube.com/watch?v=wW1u_MmtSA0

160. Sentell TL, Halpin HA. Importance of adult literacy in understanding health disparities. J Gen Intern Med. 2006 Aug;21(8):862-6. doi: 10.1111/j.1525-1497.2006.00538.x. PMID: 16881948; PMCID: PMC1831569.

161. Boonstra MD, Reijneveld SA, Foitzik EM, Westerhuis R, Navis G, de Winter AF. How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies. Nephrol Dial Transplant. 2020 Dec 22;36(7):1207–21. doi: 10.1093/ndt/gfaa273. Epub ahead of print. PMID: 33351936; PMCID: PMC8237988.

162. Hanford E. Hard Words: Why aren't kids being taught to read? APM Reports. 2018 September 10 [cited 2021 December 31]. Available from: https://www.apmreports.org/episode/2018/09/10/hard-words-why-american-kids-arent-being-taught-to-read

163. Satullo S. Bethlehem schools set a bold reading goal 5 years ago. How close have they gotten? Lehigh Valley Live. 2020 March 10 [cited 2021 December 31]. Available from: https://www.lehighvalleylive.com/news/2020/03/bethlehem-schools-set-a-bold-reading-goal-5-years-ago-how-close-have-they-gotten.html

164. Merlin M. 'This is proof everybody can do it': Majority of Easton's kindergartners hit benchmarks, regardless of which school they go to. The Morning Call. 2019 Jun 25 [cited 2021 December 31]. Available from: https://www.mcall.com/news/education/mc-nws-easton-kindergarten-scores-20190625-2iwg43ywdbc5hjcqnjt3izjzk4-story.html

165. Cotte S. Case Study: Bethlehem Area School District Extends Literacy Shifts into the Adolescent Level. Keys to Literacy. 2024 May 14 [cited 2025 June 22]. Available from: https://keystoliteracy.com/blog/case-study-bethlehem-area-school-district-extends-literacy-shifts-into-the-adolescent-level/

166. Nguyen TH, Paasche-Orlow MK, McCormack LA. The State of the Science of Health Literacy Measurement. Stud Health Technol Inform. 2017;240:17-33. PMID: 28972507; PMCID: PMC6082165.

167. Health Literacy Measurement Tools (Revised). Agency for Healthcare Research and Quality, Rockville, MD. [cited 2021 Dec 31]. Available from: https://www.ahrq.gov/health-literacy/research/tools/index.html

168. Grant CH, Salim E, Lees JS, Stevens KI. Deprivation and chronic kidney disease-a review of the evidence. Clin Kidney J. 2023 Feb 28;16(7):1081-1091. doi: 10.1093/ckj/sfad028. PMID: 37398697; PMCID: PMC10310512.

169. Norton JM, Moxey-Mims MM, Eggers PW, Narva AS, Star RA, Kimmel PL, et al. Social Determinants of Racial Disparities in CKD. J Am Soc Nephrol. 2016 Sep;27(9):2576-95. doi: 10.1681/ASN.2016010027. Epub 2016 May 13. PMID: 27178804; PMCID: PMC5004663.

170. Rothstein R. The Making of Ferguson: Public Policies at the Root of its Troubles. The Economic Policy Institute. 2014 October 15 [cited 2022 May 22]. Available from: https://www.epi.org/publication/making-ferguson/

171. Kemp J, Cisneros H, co-chairs. The Future of Fair Housing: Report of the National Commission on Fair Housing and Equal Opportunity. 2008 December [cited 2022 Jan 20]. Available from: https://www.prrac.org/projects/fair_housing_commission/The_Future_of_Fair_Housing.pdf

172. Baumgartner JC, Aboulafia GN, Getachew Y, et al. Inequities in Health and Health Care in Black and Latinx/Hispanic Communities: 23 Charts. The Commonwealth Fund. 2021 June [cited 2024 February 15]. Available from: https://www.commonwealthfund.org/sites/default/files/2021-06/Baumgartner_racial_disparities_chartbook_v2.pdf

173. Sampson RJ, Winter AS. The Racial Ecology of Lead Poisoning. Du Bois Review: Social Science Research on Race 13 (2016): 261 - 283 [cited 2022 July 19]. Available from: https://www.semanticscholar.org/paper/THE-RACIAL-ECOLOGY-OF-LEAD-POISONING-Sampson-Winter/9cfd36dbbfd11c7b954b887929023ef40db3f403

174. Yeter D, Banks EC, Aschner M. Disparity in Risk Factor Severity for Early Childhood Blood Lead among Predominantly African-American Black Children: The 1999 to 2010 US NHANES. Int J Environ Res Public Health. 2020 Feb 28;17(5):1552. doi: 10.3390/ijerph17051552. PMID: 32121216; PMCID: PMC7084658.

175. Levin R, Zilli Vieira CL, Rosenbaum MH, Bischoff K, Mordarski DC, Brown MJ. The urban lead (Pb) burden in humans, animals and the natural environment. Environ Res. 2021 Feb;193:110377. doi: 10.1016/j.envres.2020.110377. Epub 2020 Oct 28. PMID: 33129862; PMCID: PMC8812512.

176. Politis MD, Yao M, Gennings C, Tamayo-Ortiz M, Valvi D, Kim-Schulze S, et al. Prenatal Metal Exposures and Associations with Kidney Injury Biomarkers in Children. Toxics. 2022 Nov 16;10(11):692. doi: 10.3390/toxics10110692. PMID: 36422900; PMCID: PMC9699100.

177. Sanders AP, Gennings C, Tamayo-Ortiz M, Mistry S, Pantic I, Martinez M, et al. Prenatal and early childhood critical windows for the association of nephrotoxic metal and metalloid mixtures with kidney function. Environ Int. 2022 Aug;166:107361. doi: 10.1016/j.envint.2022.107361. Epub 2022 Jun 27. PMID: 35797845; PMCID: PMC9792626.

178. Rana MN, Tangpong J, Rahman MM. Toxicodynamics of Lead, Cadmium, Mercury and Arsenic- induced kidney toxicity and treatment strategy: A mini review. Toxicol Rep. 2018 May 26;5:704-713. doi: 10.1016/j.toxrep.2018.05.012. PMID: 29992094; PMCID: PMC6035907.

179. Orr SE, Bridges CC. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. Int J Mol Sci. 2017 May 12;18(5):1039. doi: 10.3390/ijms18051039. PMID: 28498320; PMCID: PMC5454951.

180. Reilly R, Spalding S, Walsh B, Wainer J, Pickens S, Royster M, et al. Chronic Environmental and Occupational Lead Exposure and Kidney Function among African Americans: Dallas Lead Project II. Int J Environ Res Public Health. 2018 Dec 14;15(12):2875. doi: 10.3390/ijerph15122875. PMID: 30558242; PMCID: PMC6313544.

181. Caverly NL. Demolishing Detroit: How Structural Racism Endures. Stanford University Press; 2025, page 6.

182. Solomon M. The Elsewhere Is Black: Ecological Violence and Improvised Life. Durham: Duke University Press; 2025.

183. Rule AD, Cornell LD, Poggio ED. Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging? Nephron Physiol. 2011;119 Suppl 1(Suppl 1):p6-11. doi: 10.1159/000328012. Epub 2011 Aug 10. PMID: 21832860; PMCID: PMC3280422.

184. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010 Sep;21(9):1422-6. doi: 10.1681/ASN.2010070730. Epub 2010 Aug 5. PMID: 20688934; PMCID: PMC7391383.

185. Baxter LL, Watkins-Chow DE, Pavan WJ, Loftus SK. A curated gene list for expanding the horizons of pigmentation biology. Pigment Cell Melanoma Res. 2019 May;32(3):348-358. doi: 10.1111/pcmr.12743. Epub 2018 Nov 6. PMID: 30339321; PMCID: PMC10413850.

186. Durso DF, Bydlowski SP, Hutz MH, Suarez-Kurtz G, Magalhães TR, Pena SD. Association of genetic variants with self-assessed color categories in Brazilians. PLoS One. 2014 Jan 8;9(1):e83926. doi: 10.1371/journal.pone.0083926. PMID: 24416183; PMCID: PMC3885524.

187. Veller C, Coop GM. Interpreting population- and family-based genome-wide association studies in the presence of confounding. PLoS Biol. 2024 Apr 11;22(4):e3002511. doi: 10.1371/journal.pbio.3002511. PMID: 38603516; PMCID: PMC11008796.

188. Robinson-Cohen C, Triozzi JL, Rowan B, He J, Chen HC, Zheng NS, et al. Genome-Wide Association Study of CKD Progression. J Am Soc Nephrol. 2023 Sep 1;34(9):1547-1559. doi: 10.1681/ASN.0000000000000170. Epub 2023 Jun 1. PMID: 37261792; PMCID: PMC10482057.

189. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002. PMID: 10075613.

190. Modification of Diet in Renal Disease Study. Form # 04: Demographic and Baseline Examination Form, Rev. 4 11/5/90. Modification of Diet in Renal Disease Study Group. 1990. Accessed: 2021 April 22. https://repository.niddk.nih.gov/media/studies/mdrd/Forms/Demographic&Baseline_Exam.pdf, page 46.

191. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004. Erratum in: Ann Intern Med. 2008 Oct 7;149(7):519. Erratum in: Ann Intern Med. 2021 Apr;174(4):584. doi: 10.7326/L21-0010. PMID: 16908915.

192. Correction: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation. Ann Intern Med. 2021 Apr;174(4):584. doi: 10.7326/L21-0010. Erratum for: Ann Intern Med. 2006 Aug 15;145(4):247-54. PMID: 33872525.

193. Modification of Diet in Renal Disease Study. Form # 03: Screening Form Instructions, Rev. 3 7/15/89, and Screening Form # 03, Rev 3 11/15/1990. Modification of Diet in Renal Disease Study Group. 1989. Accessed April 22, 2021. https://repository.niddk.nih.gov/media/studies/mdrd/Forms/Screening.pdf

194. NIH Policy on Reporting Race and Ethnicity Data: Subjects in Clinical Research, Release Date: August 8, 2001, Notice: NOT-OD-01-053, https://grants.nih.gov/grants/guide/notice-files/not-od-01-053.html

195. Burke CO, Corwin RW. Response to Correction: MDRD Staff Assigned "Race" By Skin Color, Ann Intern Med. 2021 [online only, 2021 April 26]. Following the "correction" at doi: 10.7326/L21-0010, Accessed: 2025 December 1.

196. Jesse Brown for Black Lives (JB4BL) Clinical Committee; Conner CK, Jain B, Khan A, Laragh ML, Lowery S, Nichols N, et al. A Step Toward Health Equity for Veterans: Evidence Supports Removing Race From Kidney Function Calculations. Fed Pract. 2021 Aug;38(8):368-373. doi: 10.12788/fp.0168. PMID: 34733089; PMCID: PMC8560098.

197. Casad BJ, Luebering JE. "Confirmation bias." Encyclopedia Britannica. 2024 January 5 [cited 2024 February 4]. Available from: https://www.britannica.com/science/confirmation-bias

198. Hunt LM, Megyesi MS. Genes, race and research ethics: who's minding the store? J Med Ethics. 2008 Jun;34(6):495-500. doi: 10.1136/jme.2007.021295. PMID: 18511627; PMCID: PMC4362790.

199. Feero WG, Steiner RD, Slavotinek A, Faial T, Bamshad MJ, Austin J, et al. **Guidance on Use of Race**, Ethnicity, and Geographic Origin as Proxies for Genetic Ancestry Groups in Biomedical Publications. ***JAMA***. 2024 Apr 16;331(15):1276-1278. doi: 10.1001/jama.2024.3737. PMID: 38470200.

200. Feero WG, Steiner RD, Slavotinek A, Faial T, Bamshad MJ, Austin J, et al. **Guidance on use of race**, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications. ***Nat Genet***. 2024 Apr;56(4):555-556. doi: 10.1038/s41588-024-01708-8. PMID: 38480924.

201. Feero WG, Steiner RD, Slavotinek A, Faial T, Bamshad MJ, Austin J, et al. **Guidance on use of race**, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications. ***Am J Hum Genet***. 2024 Apr 4;111(4):621-623. doi: 10.1016/j.ajhg.2024.03.003. Epub 2024 Mar 12. PMID: 38479392; PMCID: PMC11023913.

202. Feero WG, Steiner RD, Slavotinek A, Faial T, Bamshad MJ, Austin J, et al. **Guidance on use of race**, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications. ***HGG Adv***. 2024 Apr 11;5(2):100282. doi: 10.1016/j.xhgg.2024.100282. Epub 2024 Mar 12. PMID: 38479390; PMCID: PMC11019354.

203. Feero WG, Steiner RD, Slavotinek A, Faial T, Bamshad MJ, Austin J, et al. **Guidance on Use of Race**, Ethnicity, and Geographic Origin as Proxies for Genetic Ancestry Groups in Biomedical Publications. ***Genet Med***. 2024 May;26(5):101118. doi: 10.1016/j.gim.2024.101118. Epub 2024 Mar 12. PMID: 38488074.

204. King ML Jr. Read Martin Luther King Jr.'s 'I Have a Dream' speech in its entirety. National Public Radio. 2023 January 16 [cited: 2024 April 25]. Available from: https://www.npr.org/2010/01/18/122701268/i-have-a-dream-speech-in-its-entirety

205. Lentin, A. (2008). Europe and the Silence about Race. European Journal of Social Theory, 11(4), 487-503. doi: 10.1177/1368431008097008

206. Relman AS. The new medical-industrial complex. N Engl J Med. 1980 Oct 23;303(17):963-70. doi: 10.1056/NEJM198010233031703. PMID: 7412851.

207. Kassirer JP, Steinbrook R. Medical journals need to fight back against Trump attacks. The Boston Globe. 2025 May 3 [cited 2025 May 6]. Available from: https://www.bostonglobe.com/2025/05/03/opinion/medical-journals-trump-medicine/

208. Shuster E. American Doctors at the Nuremberg Medical Trial. Am J Public Health. 2018 Jan;108(1):47-52. doi: 10.2105/AJPH.2017.304104. Epub 2017 Nov 21. PMID: 29161059; PMCID: PMC5719680.

209. Dixon-Woods M, Ashcroft RE. Regulation and the social licence for medical research. Med Health Care Philos. 2008 Dec;11(4):381-91. doi: 10.1007/s11019-008-9152-0. Epub 2008 Jul 17. PMID: 18633729

210. Klitzman R. Institutional review board community members: who are they, what do they do, and whom do they represent? Acad Med. 2012 Jul;87(7):975-81. doi: 10.1097/ACM.0b013e3182578b54. PMID: 22622206; PMCID: PMC3549463.

211. Washington HA. Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present. New York, Doubleday, 2006. ISBN 9780767915472.

212. Madara J. Reckoning with medicine's history of racism. American Medical Association, Leadership Viewpoints. 2021 February 17 [cited 2025 February 6]. Available from: https://www.ama-assn.org/about/leadership/reckoning-medicine-s-history-racism

213. Baker R, Wynia MK. Living Histories of Structural Racism and Organized Medicine. AMA J Ethics. 2021 Dec 1;23(12):E995-1003. doi: 10.1001/amajethics.2021.995. PMID: 35072617.

214. Reede JY, Williams WW, Jones DS, Kerr MB, Podolsky SH, Hammonds E, et al. Racism, Medicine, and *NEJM* since 1812 - The Historical Roots of Injustice in Medicine, Symposium 1. N Engl J Med. 2024 Jun 27;390(24):e62. doi: 10.1056/NEJMp2406794. PMID: 38924729.

215. Willoughby CDE, Hall D, Hammonds EM, Podolsky SH. John Collins Warren - Journal Founder, Institution Builder, and Racial Theorist. N Engl J Med. 2025 Jun 12;392(22):2277-2281. doi: 10.1056/NEJMms2415759. PMID: 40499176.

216. Jones DS, Podolsky SH, Bannon Kerr M, Hammonds E. Slavery and the *Journal* - Reckoning with History and Complicity. N Engl J Med. 2023 Dec 7;389(23):2117-2123. doi: 10.1056/NEJMp2307309. PMID: 38055250.

217. McFarling UL. New England Journal of Medicine reckons with its racist past and complicity in slavery. Stat News. 2023 December 6 [cited 2025 May 10]. Available from: https://www.statnews.com/2023/12/06/new-england-journal-medicine-addresses-racist-past-slavery-ties/

218. Rakhra A, Ogedegbe G, Williams O, Onakomaiya D, Ovbiagele B. Representation of Racial/ Ethnic Minority Individuals in the Leadership of Major Medical Journals. J Health Dispar Res Pract. 2021 Fall;14(4):69-81. PMID: 35444862; PMCID: PMC9017797.

219. Keeys M, Baca J, Maybank A. Race, Racism, and the Policy of 21st Century Medicine. Yale J Biol Med. 2021 Mar 31;94(1):153-157. PMID: 33795992; PMCID: PMC7995954.

220. Aaron DG, Stanford FC. Medicine, structural racism, and systems. Soc Sci Med. 2022 Apr;298:114856. doi: 10.1016/j.socscimed.2022.114856. Epub 2022 Feb 28. PMID: 35282989; PMCID: PMC9124607.

221. Nuriddin A, Mooney G, White AIR. Reckoning with histories of medical racism and violence in the USA. Lancet. 2020 Oct 3;396(10256):949-951. doi: 10.1016/S0140-6736(20)32032-8. PMID: 33010829; PMCID: PMC7529391.

222. Bassett MT. Public Health Meets the Problem of the Color Line. Am J Public Health. 2017 May;107(5):666-667. doi: 10.2105/AJPH.2017.303714. PMID: 28398798; PMCID: PMC5388967.

223. Bassett MT. #BlackLivesMatter--a challenge to the medical and public health communities. N Engl J Med. 2015 Mar 19;372(12):1085-7. doi: 10.1056/NEJMp1500529. Epub 2015 Feb 18. PMID: 25692912.

224. Lorde, A. The Master's Tools Will Never Dismantle the Master's House. Penguin Classics; 2018. [cited 2026 January 11] Available from: https://theanarchistlibrary.org/library/audre-lorde-the-master-s-tools-will-never-dismantle-the-master-s-house.pdf

225. Duster T. Medicine. Race and reification in science. Science. 2005 Feb 18;307(5712):1050-1. doi: 10.1126/science.1110303. PMID: 15718453.

226. Mulinari S, Vilhelmsson A, Ozieranski P, Bredström A. Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU. Soc Sci Med. 2021 Jul;280:114049. doi: 10.1016/j.socscimed.2021.114049. Epub 2021 May 20. PMID: 34044186.

227. Netherland J, Hansen H. White opioids: Pharmaceutical race and the war on drugs that wasn't. Biosocieties. 2017 Jun;12(2):217-238. doi: 10.1057/biosoc.2015.46. Epub 2017 Jun 28. PMID: 28690668; PMCID: PMC5501419.

228. Mulinari S, Bredström A. Race in clinical trials in Sweden: How regulatory and medical standards in clinical research trump the post-racial discourse. Sociol Health Illn. 2024 Feb;46(2):315-332. doi: 10.1111/1467-9566.13709. Epub 2023 Sep 12. PMID: 37699725.

229. Washington HA. Flacking for Big Pharma: Drugmakers don't just compromise doctors; they also undermine top medical journals and skew medical research. American Scholar. 2011 June 3 [cited: 2022 November 8]. Available from: https://theamericanscholar.org/flacking-for-big-pharma/

230. Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017 Aug 16;12(8):e0182613. doi: 10.1371/journal.pone.0182613. PMID: 28813502; PMCID: PMC5559086.

231. Emanuel EJ. The cost of marginal medicine is too high. MedGenMed. 2005 Dec 12;7(4):67. PMID: 16614689; PMCID: PMC1681708.

232. Witzig R. The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med. 1996 Oct 15;125(8):675-9. doi: 10.7326/0003-4819-125-8-199610150-00008. PMID: 8849153.

233. Kahn J. Harmonizing Race: Competing Regulatory Paradigms of Racial Categorization in International Drug Development. Santa Clara J Int'l Law, 2006 Dec 9;5(1):34-56. Available from: https://digitalcommons.law.scu.edu/scujil/vol5/iss1/3

234. Yang M, Kondo T, Dewan P, Desai AS, Sibulo AS Jr, Lam CSP, et al. Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance. J Am Heart Assoc. 2025 Jun 17;14(12):e037810. doi: 10.1161/JAHA.124.037810. Epub 2025 Jun 11. PMID: 40497494; PMCID: PMC12229099.

235. Bellato A, Raduà J, Stocker A, Lockman MS, Lall A, Ravisankar V, et al. Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders: A Meta-Analysis. JAMA Psychiatry. 2025 Jul 1;82(7):663-670. doi: 10.1001/jamapsychiatry.2025.0666. PMID: 40332916; PMCID: PMC12060014.

236. Facts and figures. Fresenius Medical Care, Profile. 2019 [cited: 2026 February 21]. Available from: https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2019/FME_Profile_2019_EN.pdf

237. Mendu ML, Weiner DE. Health Policy and Kidney Care in the United States: Core Curriculum 2020. Am J Kidney Dis. 2020 Nov;76(5):720-730. doi: 10.1053/j.ajkd.2020.03.028. Epub 2020 Aug 5. PMID: 32771281.

238. Epstein EJ. Have you ever tried to sell a diamond? The Atlantic [Internet]. 1982 Feb [cited 2026 March 17]. Available from: https://www.theatlantic.com/past/issues/82feb/8202diamond1.htm.

239. Wilson M. DaVita helped craft new bill to fix "loophole" left by Supreme Court ruling, documents show. Politico. 2022 August 9 [cited 2026 February 26]. Available from: https://www.politico.com/news/2022/08/09/davita-helped-craft-new-bill-to-fix-loophole-left-by-supreme-court-loss-documents-show-00050705

240. Young S. Dialysis Industry Spends Millions, Emerges as Power Player in California Politics. KFF Health News. 2020 December 10, [cited 2026 February 26]. Available from: https://kffhealthnews.org/news/article/dialysis-industry-spends-millions-emerges-as-power-player-in-california-politics/

241. Arnold C, Price LC. Kidney Dialysis Is a Booming Business—Is It Also a Rigged One? Scientific American. 2020 December 14 [cited 2022 July 27]. Available from: https://www.scientificamerican.com/article/kidney-dialysis-is-a-booming-business-is-it-also-a-rigged-one1/

242. Fields R. In Dialysis, Life-Saving Care at Great Risk and Cost. ProPublica. 2010 November 9 [cited 2026 February 26]. Available from: https://www.propublica.org/article/in-dialysis-life-saving-care-at-great-risk-and-cost

243. Alsan M, Neberai Y. Why doesn't the United States have national health insurance? The role of the American Medical Association [Internet]. Cambridge, MA: National Bureau of Economic Research. 2024 September [cited 2026 February 15]. (NBER Working Paper Series, No. 32484). Available from: https://www.nber.org/papers/w32484

244. Kuttner R. Free Markets, Besieged Citizens. The New York Review of Books. 2022 July 21 [cited 2023 June 18]. Available from: https://www.nybooks.com/articles/2022/07/21/free-markets-besieged-citizens-gerstle-kuttner/

245. Nicholls SG, Hayes TP, Brehaut JC, McDonald M, Weijer C, Saginur R, Fergusson D. A Scoping Review of Empirical Research Relating to Quality and Effectiveness of Research Ethics Review. PLoS One. 2015 Jul 30;10(7):e0133639. doi: 10.1371/journal.pone.0133639. PMID: 26225553; PMCID: PMC4520456.

246. Cope EL, Khan M, Millender S. Trust In Health Care: Insights From Ongoing Research. Health Affairs Forefront. 2022 January 11 [cited: 2023 May 12]. DOI: 10.1377/forefront.20220110.928032

247. Bertram M, Brandt US, Hansen RK, Svendsen GT. Does higher health literacy lead to higher trust in public hospitals? Int J Equity Health. 2021 Sep 16;20(1):209. doi: 10.1186/s12939-021-01528-w. PMID: 34530812; PMCID: PMC8447678.

248. Frier S, Burrows P. In tech world, minorities remain quiet about lack of diversity. Delaware Online. 2014 November 15 [cited: 2023 December 3]. Available from: https://www.delawareonline.com/story/money/business/2014/11/15/tech-world-minorities-remain-quiet-lack-diversity/19085519/

249. Alcabes P. Experimental Overreach: Why doctors and researchers must ask for consent. The American Scholar. 2021 April 3 [cited: 2023 February 2]. Available from: https://theamericanscholar.org/experimental-overreach/

250. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement. BMJ. 2003 May 31;326(7400):1189-92. doi: 10.1136/bmj.326.7400.1189. PMID: 12775621; PMCID: PMC1126053.

251. Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ. 2015 Jun 2;350:h2942. doi: 10.1136/bmj.h2942. [The PMID for this reference, 26036926, is inexplicably broken.] Available from: https://www.bmj.com/content/350/bmj.h2942

252. Angell M. In medical research, financial conflicts of interest do matter. The Boston Globe. 2016 April 11 [cited 2022 October 9]. Available from: https://www.bostonglobe.com/opinion/2016/04/11/medical-research-financial-conflicts-interest-matter/FfGc04GpdBXztO6m3kcT1I/story.html

253. McNutt M, Córdova FA, Allison DB. The Strategic Council for Research Excellence, Integrity, and Trust. Proc Natl Acad Sci U S A. 2021 Oct 12;118(41):e2116647118. doi: 10.1073/pnas.2116647118. PMID: 34611023; PMCID: PMC8521670.

254. Kassirer JP. Commentary: Disclosure's failings: what is the alternative? Acad Med. 2009 Sep;84(9):1180-1. doi: 10.1097/ACM.0b013e3181b17e93. PMID: 19707054.

255. Lexchin J, Fugh-Berman A. A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough. J Gen Intern Med. 2021 Oct;36(10):3194-3198. doi: 10.1007/s11606-021-06657-0. Epub 2021 Mar 10. PMID: 33694070; PMCID: PMC8481515.

256. Chengappa M, Herrmann S, Poonacha T. Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines. Kidney Int Rep. 2020 Dec 31;6(3):768-774. doi: 10.1016/j.ekir.2020.12.014. PMID: 33732991; PMCID: PMC7938069.

257. Dal-Ré R, Caplan AL, Marusic A. Editors' and authors' individual conflicts of interest disclosure and journal transparency. A cross-sectional study of high-impact medical specialty journals. BMJ Open. 2019 Jul 23;9(7):e029796. doi: 10.1136/bmjopen-2019-029796. PMID: 31340971; PMCID: PMC6661703.

258. Facher L. More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows. Stat News. 2021 June 9 [cited: 2023 July 19]. Available from: https://www.statnews.com/feature/prescription-politics/federal-full-data-set/

259. Marks JH. Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation. J Bioeth Inq. 2020 Jun;17(2):173-189. doi: 10.1007/s11673-020-09982-x. Epub 2020 Jul 13. PMID: 32661741; PMCID: PMC7357445.

260. McCoy MS, Carniol M, Chockley K, Urwin JW, Emanuel EJ, Schmidt H. Conflicts of Interest for Patient-Advocacy Organizations. N Engl J Med. 2017 Mar 2;376(9):880-885. doi: 10.1056/NEJMsr1610625. PMID: 28249131.

261. FDA, FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends. Washington, DC: Food and Drug Administration. 2018 [cited 2022 August 14]. Available from: https://www.fda.gov/media/111695/download

262. The High Price of Aduhelm's Approval: An Investigation into FDA's Atypical Review Process and Biogen's Aggressive Launch Plans. The Committee on Oversight and Reform and Committee on Energy and Commerce. 2022 December. Available from: https://democrats-energycommerce.house.gov/sites/democrats.energycommerce.house.gov/files/documents/Final%20Aduhelm%20Report_12.29.22.pdf

263. Belluck P. Congressional Inquiry into Alzheimer's Drug Faults Its Maker and F.D.A.he New York Times. 2022 December 29 [cited: 2022 December 30]. Available from: https://www.nytimes.com/2022/12/29/health/alzheimers-drug-aduhelm-biogen.html

264. Saltzman J. Biogen pays $900m to settle whistle-blower suit over kickbacks. The Boston Globe. 2022 September 26 [cited 2022 September 27]. Available from: https://www.bostonglobe.com/2022/09/26/business/biogen-pays-900m-settle-whistleblower-suit-over-kickbacks/

265. Angell M. Drug firms' funds should be out of the education equation altogether. The Boston Globe. 2015 August 12 [cited 2022 October 9]. Available from https://www.bostonglobe.com/opinion/letters/2015/08/11/drug-firms-funds-should-out-education-equation-altogether/RTtxCnM6OtilCyUTyRFL8K/story.html

266. Yang Y, Creon A, Levey AS, Faucon AL, Caldinelli A, Evans M, et al. Population-based estimated Glomerular Filtration Rate distributions and associated health outcomes provide opportunities for early identification of and primary prevention of chronic kidney disease. Kidney Int. 2026 Jan 16:S0085-2538(25)00989-5. doi: 10.1016/j.kint.2025.11.009. Epub ahead of print. PMID: 41543464.

267. den Hartog JR, Reese PP, Cizman B, Feldman HI. The costs and benefits of automatic estimated glomerular filtration rate reporting. Clin J Am Soc Nephrol. 2009 Feb;4(2):419-27. doi: 10.2215/CJN.04080808. Epub 2009 Jan 28. PMID: 19176794; PMCID: PMC2637597.

268. Angell M. Drug Companies & Doctors: A Story of Corruption. The New York Review of Books. 2009 January 15 [Cited 2022 October 3]. Available from: https://www.nybooks.com/articles/2009/01/15/drug-companies-doctorsa-story-of-corruption/

269. Angell M. Is academic medicine for sale? N Engl J Med. 2000 May 18;342(20):1516-8. doi: 10.1056/NEJM200005183422009. PMID: 10816191.

270. Horton R. “Offline: What is medicine’s 5 sigma?” The Lancet. 2015 April 11 [cited 2022 April 22]. doi: 10.1016/S0140-6736(15)60696-1

271. De Vries RG, Kim SY. Bioethics and the sociology of trust: introduction to the theme. Med Health Care Philos. 2008 Dec;11(4):377-9. doi: 10.1007/s11019-008-9158-7. Epub 2008 Jul 16. PMID: 18629608; PMCID: PMC2712295.

272. 45 CFR 46.111(a)(3). United States Code of Federal Regulations, Title 45 - Public Welfare, Part 46 – Protection of Human Subjects, Subpart A - Basic HHS Policy for Protection of Human Research Subjects, § 46.111 Criteria for IRB approval of research. [cited 2023 April 29]. Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.111#p-46.111(a)(3)

273. Rencher WC, Wolf LE. Redressing past wrongs: changing the common rule to increase minority voices in research. Am J Public Health. 2013 Dec;103(12):2136-40. doi: 10.2105/AJPH.2013.301356. Epub 2013 Oct 17. PMID: 24134384; PMCID: PMC3828970.

274. Bracken-Roche D, Bell E, Macdonald ME, Racine E. The concept of 'vulnerability' in research ethics: an in-depth analysis of policies and guidelines. Health Res Policy Syst. 2017 Feb 7;15(1):8. doi: 10.1186/s12961-016-0164-6. Erratum in: Health Res Policy Syst. 2017 Apr 3;15(1):29. PMID: 28173859; PMCID: PMC5297186.

275. Murphy M, Ding A, Berk J, Rich J, Bayliss G. Kidney Disease among People Who Are Incarcerated. Clin J Am Soc Nephrol. 2021 Nov;16(11):1766-1772. doi: 10.2215/CJN.01910221. Epub 2021 Jun 16. PMID: 34135025; PMCID: PMC8729426.

276. Ervin AM, Taylor HA, Ehrhardt S. NIH Policy on Single-IRB Review - A New Era in Multicenter Studies. N Engl J Med. 2016 Dec 15;375(24):2315-2317. doi: 10.1056/NEJMp1608766. PMID: 27974026; PMCID: PMC5234329.

277. Emanuel EJ, Lemmens T, Elliot C. Should society allow research ethics boards to be run as for-profit enterprises? PLoS Med. 2006 Jul;3(7):e309. doi: 10.1371/journal.pmed.0030309. Epub 2006 Jul 25. PMID: 16848618; PMCID: PMC1518668.

278. Kaplan S. In clinical trials, for-profit review boards are taking over for hospitals. Should they? Stat News. 2016 July 6 [cited 2022 November 30]. Available from: https://www.statnews.com/2016/07/06/institutional-review-boards-commercial-irbs/

279. Stephens L, Redvers N, Taualii M, Cimino A, Boynton K, Kelliher A, Mars-Martins HA, et al. Building Equitable Partnerships Between Industry Sponsors and Indigenous Communities to Enhance Engagement in Clinical Trials. Clin Ther. 2025 Nov;47(11):981-991. doi: 10.1016/j.clinthera.2025.08.013. Epub 2025 Sep 25. PMID: 41006157.

280. Fins JJ. COVID-19 makes clear that bioethics must confront health disparities. The Conversation [Internet]. 2020 July 8, 2020 [cited 2022 February 16]. Available from: https://theconversation.com/covid-19-makes-clear-that-bioethics-must-confront-health-disparities-142136

281. 45 CFR 46.104(d). United States Code of Federal Regulations, Title 45 - Public Welfare, Part 46 – Protection of Human Subjects, Subpart A - Basic HHS Policy for Protection of Human Research Subjects, § 46.104(d)(4)(i) - Secondary research for which consent is not required. [cited 2022 April 3]. Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46#p-46.104(d)(4)(i)

282. Bick AG, Akwo E, Robinson-Cohen C, Lee K, Lynch J, Assimes TL, et al; VA Million Veteran Program. Association of *APOL1* Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program. Circulation. 2019 Sep 17;140(12):1031-1040. doi: 10.1161/CIRCULATIONAHA.118.036589. Epub 2019 Jul 24. PMID: 31337231; PMCID: PMC6754626.

283. Meyer MC. Probability and mathematical statistics: theory, applications, and practice in R. Philadelphia: SIAM; 2019. ISBN: 9781611975789

284. Rowland C, Romm T. Merck sues over Medicare price negotiations. The Washington Post. 2023 June 6 [cited: 2023 June 19]. Available from: https://www.washingtonpost.com/business/2023/06/06/merck-medicare-price-controls/

285. Kimball S. Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court. CNBC. 2023 June 20 [cited: 2023 July 19]. Available from: https://www.cnbc.com/2023/06/20/drug-prices-drugmakers-aim-to-fight-medicare-negotiations-at-scotus.html

286. Emanuel EJ. Rand Corporation, Tenth Albert P. Williams Lecture on Health Policy. 2018 October 17 [cited 2023 February 26]. Available from: [Blog overview] https://www.rand.org/blog/rand-review/2019/05/why-are-drug-prices-so-high-in-the-united-states.html and [Audio] https://www.rand.org/multimedia/audio/2018/10/17/whats-the-fair-price-of-a-drug.html

287. Levi J, Cross S, Ramesh N, Venter F, Hill A. How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Ahead of Patent Expiry. medRxiv 2026.03.04.26347508; doi: https://doi.org/10.64898/2026.03.04.26347508

288. Relman A, Angell M. America's other drug problem. The New Republic. 2002 December 16 [cited: 2023 January 29]. Available from: https://static.poder360.com.br/2021/08/relmanangell_Rxdrugs.pdf

289. Menzel PT. Ethical Drug Pricing. The Hastings Center for Bioethics, Bioethics Briefings. 2025 February 19 [cited 2026 March 12]. Available from: https://www.thehastingscenter.org/briefingbook/ethical-drug-pricing/

290. Barrueta T. A Brief History of Drug Pricing. Kaiser Permanente, Partnership for Quality Care. 2015 March 15 [cited 2026 March 12]. Available from: https://achp.org/wp-content/uploads/Tony-Barrueta-Presentation-5_15_15.pdf

291. Majeed A, Abbasi K. Medical journals should use the term "public health and social measures". BMJ. 2025 Mar 4;388:r409. doi: 10.1136/bmj.r409. PMID: 40037652.

292. Bundled Payments. Centers for Medicare & Medicaid Services. 2025 January 7 [cited: 2026 February 23]. Available from: https://www.cms.gov/priorities/innovation/key-concepts/bundled-payments

293. Unbundling Health Care Claims. Practical Law, Thompson Reuters. [cited: 2026 February 23]. Available from: https://content.next.westlaw.com/Glossary/PracticalLaw/I90b358dd597c11eaadfea82903531a62?transitionType=Default&contextData=(sc.Default)

294. Nicholls SG, Carroll K, Zwarenstein M, Brehaut JC, Weijer C, Hey SP, et al; Ethics of Pragmatic Trials project. The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders. Trials. 2019 Dec 23;20(1):765. doi: 10.1186/s13063-019-3899-x. PMID: 31870433; PMCID: PMC6929346.

295. Federico CA, Heagerty PJ, Lantos J, O'Rourke P, Rahimzadeh V, Sugarman J, et al. Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials. Contemp Clin Trials. 2022 Apr;115:106703. doi: 10.1016/j.cct.2022.106703. Epub 2022 Feb 15. PMID: 35176501; PMCID: PMC9272561.

296. Lantos JD, Wendler D, Septimus E, Wahba S, Madigan R, Bliss G. Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials. Clin Trials. 2015 Oct;12(5):485-93. doi: 10.1177/1740774515597687. Epub 2015 Sep 15. PMID: 26374686; PMCID: PMC4703320.

297. Lie RK, Chan FKL, Grady C, Ng VH, Wendler D. Comparative effectiveness research: what to do when experts disagree about risks. BMC Med Ethics. 2017 Jun 19;18(1):42. doi: 10.1186/s12910-017-0202-0. PMID: 28629343; PMCID: PMC5477349.

298. Nicholls SG, Carroll K, Goldstein CE, Brehaut JC, Weijer C, Zwarenstein M, et al. Patient Partner Perspectives Regarding Ethically and Clinically Important Aspects of Trial Design in Pragmatic Cluster Randomized Trials for Hemodialysis. Can J Kidney Health Dis. 2021 Jul 26;8:20543581211032818. doi: 10.1177/20543581211032818. PMID: 34367647; PMCID: PMC8317238.

299. Dal-Ré R, Carcas AJ, Carné X, Wendler D. Patients' beliefs regarding informed consent for low-risk pragmatic trials. BMC Med Res Methodol. 2017 Sep 18;17(1):145. doi: 10.1186/s12874-017-0424-3. PMID: 28923007; PMCID: PMC5604493.

300. Nix HP, Weijer C, Brehaut JC, Forster D, Goldstein CE, Taljaard M. Informed consent in cluster randomised trials: a guide for the perplexed. BMJ Open. 2021 Sep 27;11(9):e054213. doi: 10.1136/bmjopen-2021-054213. PMID: 34580104; PMCID: PMC8477335.

301. Zhang JZ, Nicholls SG, Carroll K, Nix HP, Goldstein CE, Hey SP, et al. Informed consent in pragmatic trials: results from a survey of trials published 2014-2019. J Med Ethics. 2021 Nov 15:medethics-2021-107765. doi: 10.1136/medethics-2021-107765. Epub ahead of print. PMID: 34782417; PMCID: PMC9107524.

302. Kalkman S, van Thiel GJ, Grobbee DE, Meinecke AK, Zuidgeest MG, van Delden JJ; Work Package 3 of the IMI GetReal Consortium. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs. Trials. 2016 Aug 22;17(1):419. doi: 10.1186/s13063-016-1546-3. PMID: 27550379; PMCID: PMC4994208.

303. Senier L, Lee R, Nicoll L. The strategic defense of physician autonomy: State public health agencies as countervailing powers. Soc Sci Med. 2017 Aug;186:113-121. doi: 10.1016/j.socscimed.2017.06.007. Epub 2017 Jun 3. PMID: 28622609; PMCID: PMC5531602.

304. Waddimba AC, Mohr DC, Beckman HB, Meterko MM. Physicians' perceptions of autonomy support during transition to value-based reimbursement: A multi-center psychometric evaluation of six-item and three-item measures. PLoS One. 2020 Apr 1;15(4):e0230907. doi: 10.1371/journal.pone.0230907. PMID: 32236139; PMCID: PMC7112234.

305. Ableson R. Corporate Giants Buy Up Primary Care Practices at Rapid Pace. The New York Times. 2023 May 8 [cited: 2023 May 23]. Available from: https://www.nytimes.com/2023/05/08/health/primary-care-doctors-consolidation.html

306. Myers SL. Is Spreading Medical Misinformation a Doctor's Free Speech Right? The New York Times. 2022 November 30 [cited 2022 November 30]. Available from: https://www.nytimes.com/2022/11/30/technology/medical-misinformation-covid-free-speech.html

307. Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the Time Needed to Provide Adult Primary Care. J Gen Intern Med. 2023 Jan;38(1):147-155. doi: 10.1007/s11606-022-07707-x. Epub 2022 Jul 1. PMID: 35776372; PMCID: PMC9848034.

308. Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, et al; Get With The Guidelines Steering Committee and Investigators. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep;35(9):541-7. doi: 10.1002/clc.22021. Epub 2012 Jun 28. PMID: 22744797; PMCID: PMC6652568.

309. Morain SR, Kraft SA, Wilfond BS, Mcguire A, Dickert NW, Garland A, Sugarman J. Toward Meeting the Obligation of Respect for Persons in Pragmatic Clinical Trials. Hastings Cent Rep. 2022 May;52(3):9-17. doi: 10.1002/hast.1391. PMID: 35763201; PMCID: PMC9704739.

310. Annas GJ. Beyond Nazi War Crimes Experiments: The Voluntary Consent Requirement of the Nuremberg Code at 70. Am J Public Health. 2018 Jan;108(1):42-46. doi: 10.2105/AJPH.2017.304103. Epub 2017 Nov 21. PMID: 29161060; PMCID: PMC5719679.

311. National Institutes of Health. Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research. 2016 June 21. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-094.html

312. Beecher HK. Ethics and clinical research. 1966. Bull World Health Organ. 2001;79(4):367-72. PMID: 11368058; PMCID: PMC2566401.

313. Hover AR. Protecting the Vulnerable. Mo Med. 2022 May-Jun;119(3):188-193. PMID: 36035566; PMCID: PMC9324706.

314. Branch T. The Civil Rights Movement. The Gilder Lehrman Institute [cited: 2026 March 22]. Available from: https://www.gilderlehrman.org/history-resources/essays/civil-rights-movement